[{"article": "Army veteran Vivian Cooke has long struggled with debilitating depression.\n\u201cSo Botox basically inhibits the muscle and calms it down, so it becomes more difficult to feel those negative emotions.\u201d\n\nThe makers of Botox recently announced plans for the final phase of testing it as a treatment for depression.\nFinzi notes previous studies show between 50 to 60 percent of patients may benefit from the treatment.\n\u201cI had less problems with depression.\u201d\n\nEven though the study she took part in is now over, she said she will continue to get Botox injections.\nCosts vary widely, but the American Society for Aesthetic Plastic Surgery said the average price for a Botox treatment in 2016 was $376.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Botox has already been promoted for \u201coff label\u201d use to treat depression for some time. HealthNewsReview.org has previously explored the marketing of botox for depression and other conditions. Not only is evidence not presented well, but the news isn\u2019t novel, either.", "answer": 0}, {"article": "Transcendental meditation involves shutting out the outside world and focusing thoughts inward, or resting while remaining alert.\nMost doctors say meditation can\u2019t hurt you, but now there\u2019s reassuring evidence that it may help you as well when it comes to warding off disease.\nMost doctors say meditation can't hurt you, but now there's reassuring evidence that it may help you as well when it comes to warding off disease.\nMORE: Mind Over Matter: Can Zen Meditation Help You Forget About Pain?\n\u201cIt\u2019s like discovering a whole new class of medications,\u201d Schneider says of the power of meditation in improving the patients\u2019 health.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story provides\u00a0a good sense of where this study sits in the universe of meditation research.", "answer": 1}, {"article": "Prescribing testosterone for age-related deficiency \u2014 which is only vaguely defined \u2014 took off in 2000. The trend was driven not by solid scientific evidence, but by the introduction of convenient, rub-on testosterone products, the first being Androgel. Many men are put on testosterone with no tests of their levels or despite tests showing normal levels, a study of Medicare claims found.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Novelty in this story is not so much about the treatment itself, which the article states has been a research focus since about the year 2000. The novelty here resides in the scope and expense of these clinical trials. The\u00a0story\u00a0makes that clear.", "answer": 1}, {"article": "Clostridium novyi flourishes in low-oxygen environments.\nA potentially dangerous bacteria appears to target malignant cells and could provide a new means of fighting cancer, a small, preliminary study reports.\nThe bacteria germinated in the cancers of 11 out of the 24 patients, with tumor cells dying off as a result.\nPatients in this clinical trial were left with the bacterial infection for one week, and then everyone was given antibiotics to kill off the Clostridium novyi-NT, Janku said.\nResearchers thought this might make the bacteria a prime candidate for cancer fighting, by keeping the infection focused on the tumor site.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not establish the novelty of the research. The abstract describes this as a \u201cfirst-in-man\u201d trial of weakened clostridium novyi spores in cancer patients.\nIn general, though, bacterial therapies for cancer tumors have been studied for decades, although only recently have safer forms been available.", "answer": 0}, {"article": "\u2022 Prostatectomy, the surgical removal of the prostate gland, which can be done with minimally invasive techniques and robotic assistance;\n\u2022 Brachytherapy, in which doctors implant numerous small radioactive seeds about the size of a grain of rice into the prostate gland using multiple large needles inserted through the skin in the operating room.\nThe SBRT study for prostate cancer was supported by a grant from the U.S. Department of Defense.\nThe study - the first trial to publish five-year results from SBRT treatment for prostate cancer - found a 98.6 percent cure rate with SBRT, a noninvasive form of radiation treatment that involves high-dose radiation beams entering the body through various angles and intersecting at the desired target.\nOther clinical trials at the UTSW Department of Radiation Oncology are seeking to expand the application of SBRT to high-risk (Stage III) prostate cancer patients.\nUTSW is currently the only accredited site in Texas at which this spacer gel can be used.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release claims that the study was the first published trial to follow patients receiving SBRT for five years.", "answer": 1}, {"article": "Currently, the U.S. Preventive Services Task Force recommends that biennial screenings start at age 50 for most women, while the American Cancer Society advises that annual screenings begin at age 45.\nAnd Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society, noted that this was an observational study that only looked at the experience of one institution.\nBut only 29 women fell into the \"never had a mammogram\" group.\nAnd the women who were screened earlier had smaller tumors.\nPort's study included more than 1,100 women diagnosed with breast cancer at the Dubin Breast Center.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes clear the distinctive aspects of this study \u2014using avoidance of more aggressive treatment regimens as a deciding factor, as opposed to the more extreme avoidance of cancer death.\n", "answer": 1}, {"article": "\"When parents have a child diagnosed with an autism spectrum disorder, one of the first questions they often ask is 'how did this happen?'\nThere are a few other genetic tests that can explain another few percentage points of autism cases.\nStill, there is much geneticists can't tell parents.\nBetween 10 percent and 15 percent of autism cases can be traced to a known genetic cause, the researchers noted.\n\"CMA should be added to first-tier genetic testing for autism spectrum disorders.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story clearly points out that genetic tests for autism are often performed, but the CMA test is relatively new.\u00a0 ", "answer": 1}, {"article": "Clots are often the cause of heart attacks, and health authorities urge people with symptoms to go to the hospital immediately so that doctors can use balloons and stents, or clot-dissolving drugs, to try to prevent heart damage.\nThe study showed there was no need for the procedure.\nBut their theory failed the test.\nEven Dr. Hochman was surprised by the results.\nHer report is the latest warning from researchers who suspect that stents are being overused and may even be causing heart attacks and deaths.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The treatment discussed in the story is not a novel treatment nor was it portrayed as such.", "answer": 1}, {"article": "Atopic dermatitis is inherited and involves patches of highly itchy skin on any part of the body.\nTrial results were also reported on Tuesday in the New England Journal of Medicine, along with an editorial that said results of the study appeared \u201ccompelling\u201d at first glance and superior to those seen in previous studies of other asthma drugs.\nThe drug also met all its secondary goals, such as improving symptoms and lung function and reducing the need for standard drugs called beta agonists.\nBut she cautioned that longer trials are needed to fully assess the drug.\nSuch patients were deemed likely to benefit from treatment.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of this drug, and of the findings, are appropriately described in the story.", "answer": 1}, {"article": "\"This is quite good news,\" Fauci said.\nThe report from the Centers for Disease Control and Prevention Friday also came with good news: Testing of vaccines for swine flu show that they work with a single dose and take effect rapidly.\nAustralian and U.S. researchers said Thursday that one dose of the new swine flu vaccine looks strong enough to protect adults \u2013 and can begin protection within 10 days of the shot.\nThe winter flu vaccine is widely available now, and U.S. health authorities urged people to get it out of the way now before swine flu shots start arriving in mid-October.\nShe said busy doctors need to have completed regular vaccinations by the time they have to deal with H1N1 shots.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThe story reports that the H1N1 flu vaccine is new and makes clear the distinction between H1N1 flu shots and seasonal flu shots.", "answer": 1}, {"article": "\"Parents often say that their biggest concern is, 'When is my child going to be back to normal again?'\nA reliable lab test would help ensure that children who have a head injury don't go back to school, or to the soccer field, before their brain has healed, Bhomia says.\nBut saliva may not be the best place to measure microRNAs, Bhomia says.\nA reliable test would help overcome a major obstacle in assessing and treating concussions, which affect more than one million children and adolescents in the U.S. each year.\nA better option, he says, might be blood samples, which tend to contain greater numbers of the genetic fragments.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "A spit test to predict the duration of concussion symptoms would indeed be new. Also, the description of the background of the independent source in the story notes that he is also working on using microRNA tests to better understand traumatic brain injury, so readers and listeners are told that other researchers are studying similar approaches.", "answer": 1}, {"article": ".\nBut self-experimenters such as Burke often don\u2019t restrict themselves to medication alone.\nNgo has experimented with piracetam himself (\u201cThe first time I tried it, I thought, \u2018Wow, this is pretty strong for a supplement.\u2019 I had a little bit of reflux, heartburn, but in general it was a cognitive enhancer.\nIt\u2019s a weird but handy trick for someone who swallows 25 pills a day, most of them purchases off the Internet.\nBut it\u2019s only one of many formulations in the racetam drug family.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There story gives perspective, mentioning that piracetam has been around for decades, though newer formulations are on the market, and that companies have recently begun marketing \u201cstacks\u201d with multiple supplements.", "answer": 1}, {"article": "Use of osteoporosis drugs, once heavily advertised by celebrity spokeswomen, has dropped by more than 50% in recent years amid reports of such serious side effects as sudden bone fractures.\n\nYet many experts say the benefits of the drugs, known as bisphosphonates, far outweigh the risks for many users.\n\nAn analysis in the New England Journal...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story focuses on an active debate, rather than on a new technique, technology, or drug. There are no claims to novelty, so we\u2019ll rate this as not applicable.", "answer": 2}, {"article": "About the National Heart, Lung, and Blood Institute (NHLBI): NHLBI, a part of the National Institutes of Health (NIH), plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders.\nThese additional results of the Systolic Blood Pressure Intervention Trial (SPRINT) appear in the current online issue of the Journal of the American Medical Association (JAMA).\nWHO: Lawrence Fine, M.D., chief of the Clinical Applications and Prevention Branch at NHLBI and a co-author of the study, is available to comment on the findings and implications of this research.\nWHAT: NIH-supported researchers are reporting additional details about a widely-publicized study that linked a systolic blood pressure target under 120 mm Hg (millimeters of mercury) with reduced cardiovascular disease and a lower risk of death.\nOther experts have supported keeping the standard treatment goal at 140 mm Hg.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release doesn\u2019t claim novelty. Instead, it makes it clear that the latest results reinforce earlier findings about blood pressure management and stresses that the latest results are \u201creporting additional details about a widely-publicized study.\u201d", "answer": 1}, {"article": "Depression rates in patients taking ketamine remained low.\nNow, in the largest study of its kind, researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego mined the FDA Adverse Effect Reporting System (FAERS) database for depression symptoms in patients taking ketamine for pain.\n\"This study extends small-scale clinical evidence that ketamine can be used to alleviate depression, and provides needed solid statistical support for wider clinical applications and possibly larger scale clinical trials.\"\nAccording to Abagyan, it is possible that another factor common to patients taking ketamine was driving the antidepressant effect, such as the fact that ketamine also relieves pain.\nBut ketamine has not been tested in a large clinical trial, and all evidence of its antidepressant effects has come from anecdotes and small studies of fewer than 100 patients.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release refers often to this study being the largest of its kind and the first \u201clarge-scale\u201d study of ketamine for depression. The second sentence might lead some people to believe that this analysis is a large clinical trial \u2014 which it is not.\nThe research is novel only in its approach to claiming a benefit where there is no clear-cut relationship.\nKetamine has been tested in several small studies and research is on-going.\nThe release establishes some novelty with this statement: \u201cWhile most researchers and regulators monitor the FAERS database for increased incidences of symptoms in order to spot potentially harmful drug side effects, we were looking for the opposite \u2014 lack of a symptom.\u201d But the fact remains, this is questionable science.", "answer": 0}, {"article": "score of 0.9 or higher at the age of 50.\nStill, the absolute risks for men with elevated scores were lower than might be expected.\nFinally, some new research offers simple, practical advice \u2014 at least for men 60 and older.\nThey still have a very low individual risk of dying from prostate cancer, judging from the new data.\nscreening, they should give peace of mind to sizable numbers of men who decide not to continue regular testing.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This story was about a readily available test; it provided information on the results of a recent study which may be useful for some men making decisions about whether to be tested and if they so chose, at what age(s).", "answer": 1}, {"article": "His \"tactile imaging system\" capitalizes on the fact that cancerous lumps tend to feel harder and less movable than harmless abnormalities such as fluid-filled cysts or fibrous nodules. The fist-sized, $1,000 machine \u2014 with an elastomer probe, a light, and a camera \u2014 acts like ultrasensitive fingertips. It measures the size, elasticity, and mobility of a breast lump, then a computer program converts the data into a score from 1 to 5, with scores under 2 likely to be benign.", "question": "Does the story establish the true novelty of the approach?", "explanation": "A quote in the final paragraph\u00a0from Dr. Won, the engineer who is developing the device, points out that \u201cMany, many companies are trying to develop breast cancer screening devices, \u2026\u00a0but this is different because we want it to be portable and simple, so it could be used in\u00a0\u2026 a doctor\u2019s office.\u201d\u00a0\nAfter reading this piece, readers have no way of knowing if this profiled device is the only one under development that is portable, simple, and inexpensive.\nElastography, the method used to identify tissue with different \u201cfeel\u201d has been under investigation for a number of years.\u00a0 Although other devices underdevelopment may be more expensive, the technology is not new or novel and was originally proposed in the 1990\u2019s", "answer": 0}, {"article": "TMS treats conditions by delivering brief, powerful magnetic field pulses that stimulate nerve cells in the brain.\nOverall, 38% of the people with the real device responded to the treatment compared with 11% of those with the sham device.\nThe approval was based on a clinical trial of 100 people with obsessive-compulsive disorder, where roughly half received treatment with TMS and the other half had a sham treatment that didn't deliver the electromagnetic pulses.\nPeople who were taking medication for OCD continued to do so for the trial.\nThe FDA first approved TMS devices for major depression in 2008, and in 2013 they were approved to treat pain associated with some types of migraine headaches.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that TMS and TMS devices aren\u2019t new, but this is the first time a TMS device can be marketed as an OCD treatment.\nHowever, the story says \u201cthere\u2019s no equivalent device already available to patients,\u201d but that doesn\u2019t appear to be accurate. There are several brands of TMS devices. Is there anything unique about this one for OCD, or was Brainsway simply the first to test it on OCD patients?", "answer": 1}, {"article": "Worse, Anderson says, \"I could feel the tumors getting bigger.\nStill, the study stands as \"a major landmark in cancer immunotherapy,\" says Dr. Bernard Fox, president of the International Society for Biological Therapy of Cancer.\nWhile far from a cure, the treatment is the first to improve survival in people with melanoma that has spread, or metastasized, says Dr. Walter Urba, director of cancer research at the Providence Cancer Center.\nOther drug companies are at work on competing versions of the immune-enhancing antibody therapy.\nResearchers linked 14 deaths to the study drugs, half caused by immune-system reactions.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of the approach is clear in the story \u2013 \"one of the first antibody-based therapies that use the body\u2019s immune defenses to destroy cancer cells\" and \"Drug companies are racing to develop competing versions of the immune-enhancing therapy, an antibody produced through genetic engineering.\"", "answer": 1}, {"article": "\"Fast and junk food seem like an easy and affordable option for busy parents, but defaulting to high-fat, high-sugar, high-calorie foods is putting their children's health and future at risk,\" Heller said.\nA more health-conscious diet was associated with small increases in IQ, she said.\nCommenting on the study, Samantha Heller, a dietitian, nutritionist and exercise physiologist in Fairfield, Conn., said that \"most of us do not realize that the foods we eat have direct consequences on brain growth, function and performance.\"\nThis is particularly true during the first three years of life when the brain is developing rapidly, the study authors explained.\nHowever, to truly understand the effect of diet on children's intelligence, further studies are needed, they said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This study is part of a fast-growing field of research into the effects of early childhood nutrition on a variety of later health outcomes. The story could have mentioned this larger context, but it didn\u2019t.", "answer": 0}, {"article": "\"I feel like I can accomplish what I want to accomplish.\nWhile the results are striking, this technology is not a guarantee of complete resolution of depressive symptoms or medication side effects.\nIt's unclear how many patients have had to stop or chosen to stop treatment for depression due to side effects.\n\u201cOnce the genetic testing became available it provided Sarah with more than just physical relief,\" says Dr. Matthew B. Stanley of the Avera Medical Group in Sioux Falls, South Dakota.\nFinally, her psychiatrist, suspicious that her body might process medication differently than most, recommended a genetic test to see why Ellis wasn\u2019t responding to the prescriptions.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story includes no information about how the Genefolio test differs, if at all, from any other genetic tests currently available.", "answer": 0}, {"article": "Prostate cancer patients had a 28 percent higher relative chance of having a fatal heart attack and a 21 percent increased chance of dying from heart disease.\nStill, these risks were low in absolute terms: researchers estimated the hormone therapies would cause an extra 10 heart problems \u2013 like chest pain or a heart attack \u2013 a year for every 1,000 prostate cancer patients.\n\"What we can do with these results is to raise a flag with hormone treatments,\" said Mieke Van Hemelrijck, a cancer epidemiologist at King's College in London and the study's lead researcher.\nHelen Rippon, head of research management at Britain's Prostate Cancer Charity, said the benefits of hormone therapy ultimately outweighed the increased risk of heart problems.\n\"What patients should do is talk about this with their doctor,\" said Michael Thun, a vice president emeritus at the American Cancer Society, who was not connected to the research.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThe story does not explain how this study is different than previous studies on this topic. Indeed, the story ignored the key finding that different hormonal therapies were associated with different heart disease risks, thus raising the possibility that treatment choices could be refined.", "answer": 0}, {"article": "Viagra, known generically as sildenafil, is sold by Pfizer Inc for erectile dysfunction and under the brand name Revatio to treat a heart condition called pulmonary hypertension.\nTests in mice genetically engineered to have a condition similar to Duchenne muscular dystrophy showed the drug could improve how the heart works, Joseph Beavoa of the University of Washington and colleagues at the University of North Carolina found.\n\u201cAlthough PDE5 inhibitors will certainly not cure DMD, the current studies suggest that they could be used in combination with current or future therapies,\u201d the researchers wrote.\nIt is not clear just how the drug is helping the mice, they reported in the Proceedings of the National Academy of Sciences, but they said it may be worth trying it as a treatment for muscular dystrophy.\nPatients with DMD lack expression of the protein dystrophin as a result of mutations in the X-linked dystrophin gene,\u201d the researchers wrote.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\n \nThe story reports the new finding of this study in its next-to-last sentence, while leading with old news. The researchers wrote that to their knowledge \u201cthis is the first report of rapid reversal by a drug treatment of the functional symptoms seen in the established cardiac dysfunction that occurs in mdx mice.\u201d But the story lead is that the drug \u201cmight help treat heart symptoms of muscular dystrophy\u201d\u2026 something that has been reported previously not only in mice, but is already being tested in people. This story does not appear to put this latest study in the proper context of other experiments.\nReference:Revatio for Heart Disease in Duchenne Muscular Dystrophy (REVERSE-DMD)http://clinicaltrials.gov/show/NCT01168908", "answer": 0}, {"article": "A new, detailed mammography exam catches more cancers while causing fewer false alarms, according to the company that sells it. The downside, some physicians say, is that it costs more and delivers twice as much radiation as traditional mammograms.\n\nTomosynthesis, or three-dimensional mammography, has been available in the U.S. since February from Hologic Inc., Bedford, Mass. In just a few months, radiologists say they are finding cancers they would have missed with the standard exam.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of the approach and of the new study is clear in the story.", "answer": 1}, {"article": "An experimental Alzheimer\u2019s drug showed positive results and raised hopes anew that pharmaceutical companies were moving closer to a medicine that could finally disrupt the disease\u2019s memory-robbing course, though a string of failures shadow the efforts.\n\nAlzheimer\u2019s has proved an especially tough drug target. Approved therapies only relieve symptoms temporarily, and one experimental treatment after another promising to stymie the neurodegeneration has ultimately failed to work. Some pharmaceutical companies, after costly failures,...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explained that this is one of many attempts to find a treatment for Alzheimer\u2019s.", "answer": 1}, {"article": "In general, the risk of developing colorectal cancer varies with age, race, ethnicity and lifestyle.\nDr. Friis emphasized that people should not start taking aspirin or NSAIDs on the basis of the new findings.\nNow, using data on more than 113,000 individuals, researchers have been trying to sort out the relationship between aspirin and NSAIDs, duration of treatment, and colorectal cancer rates.\nNonaspirin NSAIDs were also protective against colorectal cancer with consistent long-term use, \u201cand there was some indication that even non-continuous use of these agents may be (marginally) effective for the prevention of colorectal cancer,\u201d Dr. Friis said.\n\u201cLow dose aspirin, already taken regularly by millions, reduces the risk of colorectal cancer,\u201d he told Reuters Health by email.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "High up in the story, the reader is told what is new about this study:\u00a0\u201cEarlier studies had suggested that aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen may help protect against colorectal cancer, but it wasn\u2019t clear how much had to be taken, and for how long, to achieve those benefits.\u201d", "answer": 1}, {"article": "An additional 1,551 women were given only materials about the importance of eating five servings of fruits and vegetables a day.\nThe government study found no benefit from a mega-veggie-and-fruit diet over the U.S. recommended serving of five fruits and vegetables a day -- more than most Americans eat.\nResearchers noted that none of the breast cancer survivors lost weight on either diet.\nHopes that a diet low in fat and chock-full of fruit and vegetables might prevent the return of breast cancer have been dashed by a seven-year experiment in more than 3,000 women.\nThat led some experts to suggest that weight loss and exercise should be the next frontier for cancer prevention research.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentions that this is a newly published study showing no evidence that a diet high in fruits and vegetables is not directly related to a decreased risk of breast cancer recurrence.\u00a0 Increasing fruits/vegetables in the diet is not a novel concept. ", "answer": 1}, {"article": "Gout occurs when uric acid builds up in the body and forms crystals in the joints or in soft tissue.\nTwo six-month clinical trials of 212 total patients showed that the drug lowered uric acid levels and reduced deposits of uric acid crystals in joints and soft tissue.\nSavient expects Krystexxa to be available by prescription later this year.\nKrystexxa is for adults with long-standing chronic gout who do not improve with or cannot tolerate other treatments.\nThe drug is administered to patients every two weeks as an intravenous infusion.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story states:\u00a0\"Krystexxa is the first-ever and only treatment approved by the FDA for adult patients who suffer with chronic gout that is refractory to conventional therapy,\" Paul Hamelin, RPh, president of Savient Pharmaceuticals, says in a news release.\"\u00a0\nBut why couldn\u2019t we have heard that from an independent expert?\u00a0 \nWe\u2019ll give the story the benefit of the doubt, but barely. ", "answer": 1}, {"article": "Their metabolism slows down, they expend fewer calories when they exercise because their muscles become much more efficient, and their thyroid hormone and adrenaline levels drop.\nThe answer, published in the current issue of The Journal of Clinical Investigation, was that the leptin trick worked.\nNow scientists think they know why.\nThe leptin would then serve as a sort of virtual fat.\nWhat is hard is to keep the weight off.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Doesn\u2019t mention that leptin \nis a purely experimental treatment \u2013 a hormone discovered in 1969.", "answer": 0}, {"article": "Anthony's asthma diminished over time, and he says he can still play soccer, run fast and breathe \"just fine.\"\nThe severity of this and the other two problems that turned up as a result of the abnormal EKGs are reason enough, Debauche says, to screen all school athletes nationwide.\nThere's no official policy from the American College of Cardiology, but officials say most members support screening student athletes.\nCardiologist Douglas Zipes, past president of the American Academy of Cardiology, says the problems kids suffer are typically electrical, like abnormal heart rhythms, or structural, like a thickening of the heart muscle.\nAfter the abnormal EKG result, however, Debauche told Anthony and his parents to closely monitor the asthma.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n       \n \nScreening athletes for heart problems is not a new idea, and the story does not suggest that it is. However, the story could have done a better job of explaining how athletes are currently screened and the role of EKGs in this process. Current American Heart Association guidelines recommend EKG and other diagnostic testing for children presumed to be at higher risk of heart problems based on personal history, family history and physical examination. The report does not provide this important information until the final sentence of the story.\u00a0 \n \n", "answer": 1}, {"article": "For more information on bisphosphonates, visit U.S. Food and Drug Administration.\nAnderson Cancer Center, was not involved in the study but put it in perspective.\nSaid Coleman: \"Zoledronic acid cannot be routinely recommended for prevention of cancer returning, but it remains a very good drug for patients where the cancer has already spread to the bone.\"\n\"As a whole, the study is negative,\" study author Dr. Robert Coleman, a professor of medical oncology at the University of Sheffield in England, said during a Thursday news conference on the findings.\nThe focus was on disease-free survival.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article made it clear that zoledronic acid is already in use for other applications.", "answer": 1}, {"article": "\u201cI couldn't even imagine first of all, not having the pain,\" she said.\nThe treatment, recently approved by the Food and Drug Administration, is called \u201ccooled radio frequency ablation\u201d and is a less drastic option for people with moderate to severe osteoarthritis pain who are not ready to have knee replacement surgery, or who have health conditions that don\u2019t make them a good candidate for surgery.\nA new, non-invasive knee procedure could bring some relief for patients suffering from debilitating chronic pain, for whom surgery is not an option.\nMarketed as \"Coolief\", the procedure uses radio frequency to target and mute the nerves responsible for sending pain signals from the arthritic knee to the brain.\nThe three current recommended approaches for knee arthritis pain are physical therapy, non-steroidal anti-inflammatory drugs such as ibuprofen and naproxen, or the opioid painkiller tramadol.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This use of radiofrequency treatment on arthritic knees does appear to be relatively new, although the technique has been employed to cope with a variety of other painful conditions, including trigeminal neuralgia, cancer pain, and spinal pain.\nAlthough radiofrequency therapy is over 60 years old, it is not used very often, apart from some procedures by cardiologists to rewire the heart\u2019s electrical system.", "answer": 1}, {"article": "However, Owens said, \u201cit\u2019s hard to do all of that in your head.\nBut the new study looked at a more sophisticated way of estimating individual patients\u2019 needs.\nA researcher not involved in the work said it was a \u201cnice study\u201d that is a first step toward showing that tailored guidelines could have benefits.\nThe problem with the old-fashioned way, he told Reuters Health in an email, is that there are many pieces of information about a patient to consider.\nAnd right now, there is a way to go before most doctors will have those systems in place.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story could have done a better job providing even a brief background on the Archimedes system and past reports about this or related research. A reader might think this was the very first news about this approach.", "answer": 0}, {"article": "scans on 991 people ages 50 to 90.\nThe question, though, was whether it helped the patients and their doctors to know what the M.R.I.\u2019s had found.\nBut in many cases it is just not known whether what is seen on a scan is the cause of the pain.\nIt\u2019s one of only two body parts \u2014 the other is the back \u2014 where there are good data on abnormalities that turn up in people who feel just fine, indicating that the abnormalities may not be so abnormal after all.\nscan, he said, radiologists should put the findings in context.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Clearly scanning is not a new idea, but it is being increasingly used earlier in the diagnostic process.", "answer": 1}, {"article": "The U.S. Preventive Services Task Force on Sunday issued new guidance for the use of cholesterol-busting statin drugs.\nThe report greatly expands the universe of people who should be screened to see if they need the medication to everyone over age 40 regardless of whether they have a history of cardiovascular disease.\nIn an opinion piece Sunday, Redberg and Mitchell Katz, deputy editor of JAMA Internal Medicine, advised everyone to take \u201ca step back\u201d and ask \u201cwhy this debate is so contentious.\u201d They suggest that the estimates of the benefits of statins may be inflated, that the drugs as an intervention are \u201cweak,\u201d and that the reports of adverse events are incomplete.\nThe task force\u2019s recommendations come on the heels of an important new study, published Saturday, that shows that people who use statins survive heart attacks better than those who do not.\nThe task force and AHA groups carry tremendous influence in medical practice and in what insurance companies will cover.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes novelty of the task force report by explaining:\nThe report greatly expands the universe of people who should be screened to see if they need the medication to everyone over age 40 regardless of\u00a0whether they have a history of cardiovascular disease.", "answer": 1}, {"article": "\u201cI was cute as button \u2014 and there was my double chin,\u201d she said.\nBy middle age, Ms. Gallagher, 51, the owner of a pet-sitting business in Torrance, Calif., was avoiding mirrors and considering liposuction, but she worried about the effects of anesthesia and the recovery time.\nThen she discovered another option: a series of fat-reducing injections intended to slim down a double chin.\nShe stood ramrod-straight, head held high, to make the bulge less apparent.\nEven as a pigtailed child, Ashley Gallagher was self-conscious about a certain fullness in her face.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story says that the drug is the first nonsurgical way of reducing double chins. We wonder if diet and exercise would also be considered nonsurgical treatments for at least some cases of double chins. But we can find no literature to support that idea. Perhaps it\u2019s too obvious an idea for anyone to have studied it?", "answer": 1}, {"article": "Oops.\nYes, there was some evidence the toxin slipped into the bloodstream or the lymph system, but Botox in the bloodstream cannot enter the brain, says its manufacturer.\nA big reason Botox and its cousins, such as Myobloc, were OK'd was that preclinical testing showed that after being injected, they did not travel along the body's highways\u2014nerve cells\u2014to the brain and spinal cord.\nOne of the deadliest poisons in nature and a possible bioterrorism agent, this neurotoxin reached the market, in very dilute doses, starting in 1989 as Botox.\nContrary to Allergan's statement that the Italian scientists \"injected the material directly into the brain,\" however, they injected the neurotoxin into facial muscles\u2014and from there it found its way to the brainstem.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did not provide a clear picture of how long botulinum toxin has been used and why.\u00a0 It was first approved by the FDA in 1989 for the treatment of two ocular conditions. \u00a0It has subsequently been approved for a variety of uses, though the story mentioned only its cosmetic uses. \u00a0", "answer": 0}, {"article": "Can a high-tech scan reveal whether Alzheimer's disease is the cause of your forgetfulness? Advocates of Positron Emission Tomography scans for the diagnosis of Alzheimer's say the scans significantly aid in the early and accurate diagnosis of the memory-robbing disease. Neurologists say PET is useful in distinguishing between Alzheimer's and a similar-acting dementia. However, opinions differ on whether the scans are useful in predicting the likelihood of Alzheimer's in people with only mild memory problems.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not comment on the novelty of PET scanning. How long have they been used for this purpose? ", "answer": 0}, {"article": "Insulin helps glucose (sugar) enter cells to provide fuel for those cells.\nThe study medications were supplied by the manufacturer of the growth hormone-releasing hormone.\nBenefits from the treatment lasted as long as people stayed on the treatment.\nWhen treatment was stopped, the benefits gradually tapered off, Baker said.\nTests to measure mental prowess were given at the start of the study, and at 10, 20 and 30 weeks after treatment began.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story at least established that the same team had done prior work with GHRH.", "answer": 1}, {"article": "Renal vein surgery can often be managed with minimally invasive laparoscopic techniques, but this is not typically advisable for an IVC thrombus (a fibrous clot), which is surgically far more complex with potentially fatal complications that can occur in the course of removing the thrombus and reconstructing the IVC.\n\"Using robotic nephrectomy, our complication rate and lack of mortalities compare reasonably with open series with no grade III to V complications, according to the Clavien system, in any patient, including no deaths.\"\nEach surgeon performed between one and ten procedures for IVC tumor thrombi which ranged from one to 11 cm in length on preoperative imaging.\nThe first known procedure using robotic surgery of renal tumors with IVC tumor thrombi was performed in 2008.\nNone of the operations was converted to open surgery and all but two patients were ambulatory on the day of or day after surgery.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release notes the history of the procedure and that this is the first multi-institutional study to examine the role of robotically assisted minimally invasive surgery for this condition.\nFrom the published study: \u201cWe report our combined experience with this procedure, to our knowledge the first multi-institutional and largest series reported to date.\u201d", "answer": 1}, {"article": "\"Because cancer cells are different to healthy ones, they produce a different mixture of chemicals.\n\"At present the only way to diagnose esophageal cancer or stomach cancer is with endoscopy.\n\"A breath test could be used as a noninvasive, first-line test to reduce the number of unnecessary endoscopies.\nMarkar added that the test needs to be validated in a bigger group before it could be used on patients.\nThe researchers said they are planning a larger trial of the breath test over the next three years.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This isn\u2019t the first research to address the possibility of using breath tests to diagnose cancer, nor is it the first research to look at using breath tests to diagnose stomach cancer. A quick search finds other journal articles that use various techniques to approach the challenge of diagnosing cancer using a patient\u2019s breath (like this one, or this one). This may well be the first breath test to look at these specific chemicals in the breath, or the first breath test to show this degree of accuracy. However, we don\u2019t know that, because the story doesn\u2019t place the new research into context: How does it fit into the broader continuum of research on using breath tests to diagnose cancers?", "answer": 0}, {"article": "Breast cancer strikes more than 180,000 women each year in the United States and kills more than 40,000, making it the most common form of cancer after skin cancer and second leading cancer killer among women.\nThe test by Decode Genetics of Reykjavik, Iceland, a respected pioneer in genetic research, promises to determine a woman's risk through a simple blood sample or cheek swab.\nAn FDA spokeswoman said the agency had just become aware of the new test and could not say whether it would take any action, though she noted that in August the agency sent a letter expressing concern to another company marketing a questionable genetic test for ovarian cancer.\nPreviously, the only tests for breast cancer risk were for relatively rare genes, leaving most women with no way to assess their individual genetic predisposition.\nWhile welcomed by some patient advocates and doctors, the $1,625 test raises concerns among others.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that there are other genetic tests, but this is one of the first for breast cancer for women who do not carry the BRCA1/2 gene. The story does not mention that there are several other risk calculators to estimate a women\u2019s risk. ", "answer": 1}, {"article": "In macular edema, fluid from those damaged vessels leaks into the macula, the part of the retina that is responsible for the straight-ahead vision important for driving, recognizing faces and reading.\nDr. Neil M. Bressler of Johns Hopkins University, the chairman of the group that conducted the trial, said a two-line improvement in vision would allow some people to read normal-size print or to drive again.\nHe said treatment with Lucentis in the clinical trial virtually eliminated those incidents.\nThe trial involved 691 patients, some of whom had both eyes treated, resulting in 854 total eyes.\nThe steroid treatment did not improve eyesight more than laser therapy alone and caused side effects.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The story was very clear that this was a new use for a medication that is already on the market. \u00a0The story provided some insight that the company underwriting the costs of this study had a very similar but less expensive drug which was FDA approved for other use. \u00a0It would have been useful to include a little more information comparing the two medications. \u00a0It might also have been nice to include some information about how the drug studied works as compared to laser treatment, the current standard.", "answer": 1}, {"article": "But another found that the stroke rate was 22 percent lower in people who ate chocolate once a week, and a third reported that death from stroke was 46 percent lower in those who ate 50 grams of chocolate once a week.\nThe health benefit may come from antioxidants called flavonoids that are present in chocolate, Saposnik said.\nAnd dietitians say too much chocolate can be harmful.\nBut the findings, based on a review of existing research, aren't conclusive, and they don't prove that chocolate is good for your heart.\nSo, should you and your sweetheart add dark chocolate to your diet?\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explained this study was a review of existing studies. ", "answer": 1}, {"article": "\u201cWe\u2019ll also advance key parts of our tobacco plan very soon,\u201d he said.\nThe move was part of a comprehensive plan the agency announced last summer to regulate tobacco and nicotine, FDA Commissioner Scott Gottlieb said on a call with reporters.\nThe FDA is seeking additional research and data for public review, Gottlieb said, as it tries to develop a nicotine product standard.\nThe comment period will be open through mid-June, said Mitch Zeller, director of FDA\u2019s Center for Tobacco Products.\nGottlieb said the FDA was also seeking public opinion on whether a product standard should be implemented all at once or gradually.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes very clear that this is a new and sweeping effort by the FDA to reduce smoking rates in the US.", "answer": 1}, {"article": "\u201cIt\u2019s a problematic study,\u201d Dr. Sacks said.\nBut, Dr. Alderman said, the new study is not the only one to find adverse effects of low-sodium diets.\nLowering salt consumption, Dr. Alderman said, has consequences beyond blood pressure.\nDr. Frank Sacks of the Harvard School of Public Health agreed and also said the study was flawed.\n\u201cThe low-salt advocates suggest that all 300 million Americans be subjected to a low-salt diet.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "", "answer": 1}, {"article": "Commenting, Professor Andreas Meyer-Lindenberg, Central Institute of Mental Health, Mannheim and member of the ECNP executive board, said: \"This work builds on previous studies that have shown a critical role of excessive activity of subregions of the temporal lobe in the generation of voice hallucinations in schizophrenia.\nThis is the first controlled trial to show an improvement in these patients by targeting a specific area of the brain and using high frequency TMS.\nTo move this into treatment, controlled trial such as the one by Dollfus and coworkers are important.\nFor the first time, scientists have precisely identified and targeted an area of the brain which is involved in \"hearing voices\", experienced by many patients with schizophrenia.\nThey have been able to show in a controlled trial that targeting this area with magnetic pulses can improve the condition in some patients.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does a good job here. For example, the release notes that TMS \u201chas been suggested as a possible way of treating the hearing of voices in schizophrenia\u2026.However, there is a lack of controlled trials to show that TMS works effectively with AVH sufferers.\u201d The release also quotes an independent source saying that \u201cThis work builds on previous studies that have shown a critical role of excessive activity of subregions of the temporal lobe in the generation of voice hallucinations in schizophrenia. To move this into treatment, controlled trial such as the one by Dollfus and coworkers are important.\u201d That\u2019s valuable context.\nHowever, there is one point that raises some confusion. The release notes that this study involved 59 patients in all, and that it has been accepted for publication in a forthcoming issue of the journal Schizophrenia Bulletin. However, a search online finds that a very similar study, by at least one of the same researchers (the only one whose name we know), involving 74 patients, was published online in the journal Neurophysiologie Clinique (Clinical Neurophysiology) in June. Is this part of the same study discussed in the release? If not, how does it differ from the study being discussed in the release? If it is the same, why was there a different number of patients?", "answer": 1}, {"article": "That compares with a 15-point decline in patients who initially received placebo and switched to IVIG, says Norman Relkin, MD, of Cornell Weill College of Medicine in New York City.\nThe findings were presented at the American Academy of Neurology meeting.\nThe IVIG treatment also appeared to slow the rate of brain shrinkage by about 45%, he tells WebMD.\nThe drug is called Gammagard.\nIt's a form of intravenous immunoglobulin, or IVIG, drugs that are usually used to treat immune system disorders.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "No extraordinary claims of novelty were made. ", "answer": 1}, {"article": "Knee surgery for a torn meniscus is done about half a million times each year in the U.S.\nOne study participant \u2014 Bob O'Keefe, 68, of suburban Boston \u2014 was glad to avoid surgery for his meniscus injury three years ago.\nResearchers at seven major universities and orthopedic surgery centers around the U.S. assigned 351 people with arthritis and meniscus tears to get either surgery or physical therapy.\nBut those who stuck with therapy had improved as much six months and one year later as those who had arthroscopic surgery right away, researchers found.\n\"There are patients who would like to get better in a 'fix me' approach\" and surgery may be best for them, said Elena Losina, another study leader from Brigham and Women's Hospital.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story could have done a better job of explaining what was new and novel about the study in question.\u00a0 The researchers wrote:\n\u201c(Two prior) landmark trials established that arthroscopic treatment was not superior to the other interventions in the treatment of knee osteoarthritis, but they did not focus on management of a symptomatic meniscal tear, which is a frequent indication for knee arthroscopy in patients with osteoarthritis of the knee. The efficacy of arthroscopic partial meniscectomy in symptomatic patients with a meniscal tear and osteoarthritis has been evaluated, to our knowledge, in only one randomized, controlled trial, which was a single-center study involving 90 patients. This study did not show a significant difference in pain relief or functional status between arthroscopic partial meniscectomy plus a physical-therapy regimen and physical therapy alone. Given the frequency and cost of arthroscopic partial meniscectomy and the paucity of data, we designed the Meniscal Tear in Osteoarthritis Research (METEOR) trial to assess the efficacy of arthroscopic partial meniscectomy as compared with a standardized physical-therapy regimen for symptomatic patients with a meniscal tear and concomitant mild-to-moderate osteoarthritis.\u201d", "answer": 0}, {"article": "Varenicline contains no nicotine.\nThis may seem like common sense, but no one had ever tested it before, she said.\n\"The trial and error approach is not optimal.\"\nAnd given how difficult it is to kick the habit, smokers need all the help they can get to succeed the first time they try, Lerman said.\nThe patch, worn on the skin, delivers a steady flow of the drug, she said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story includes a comment from the researcher that this was an obvious question to study, but \u201cno one had done it.\u201d Again, we would have liked for someone other than the author to agree and add credibility. However, the story\u2019s description of the study\u2019s novelty appears accurate.", "answer": 1}, {"article": "Article reference: Thomas L. Jang, Neal Patel, Izak Faiena, Kushan Radadia, Dirk F. Moore, Sammy E. Elsamra, Eric A.\n\"This important study demonstrates that many men with high-risk prostate cancer derive a survival advantage through a multi-modality approach to their disease.\nAnother interesting finding from the research was that slightly more than half of men diagnosed with the disease did not receive combination therapies for their prostate cancer.\nThey found that 10 years after treatment, 89 percent of the prostate removal plus radiation group was still alive.\n\"For high-risk prostate patients we started the use of aggressive radiation therapy after surgery 20 years ago,\" said Adam Dicker, Senior Vice President and Chair of the Department of Enterprise Radiation Oncology at Jefferson Health, who was not involved in the study.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release stated: \u201cFor the first time, researchers have shown that more patients live longer if treated with the combination of prostate removal plus radiation therapy.\u201d\nIt also called this \u201cthe largest population-based retrospective study to date\u201d and mentioned that \u201cseveral large clinical trials\u201d on the topic are nearing completion.\nWhile some of these descriptions tend to inflate the importance of the study, those concerns have been addressed elsewhere.", "answer": 1}, {"article": "Computed tomography coronary angiography (CTCA), is a high-resolution X-ray of the heart that can be used to diagnose the reason for angina, or chest pain, symptoms and clarify what other treatments might be needed.\nAlthough getting CTCA is associated with a lower likelihood of having a heart attack later on, its effects on symptoms and quality of life may vary, the researchers note in the journal Heart.\nWhen the CTCA results revealed something less than a blockage, so-called nonobstructive disease, as the cause for the patient\u2019s chest pain, patients\u2019 quality of life got worse in the following weeks and months.\n\u201cThis suggests that being reassured that all is normal is highly valued by patients and CTCA really helps provide this reassurance.\n\u201cIn my opinion, CTCA does have added value in the diagnostic process (improved decision making), it is less invasive than coronary angiography (CAG), and can provide more clarity in the cardiac symptoms experienced by patients,\u201d Mommersteeg concluded.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story appropriately characterizes the research as providing new data on how patients feel, their symptoms and quality of life, depending on whether or not CTCA was used to further clarify their chest pain diagnoses. It does not claim that CTCA is itself new. It would have been nice to see some reference to other research into the quality of life of chest pain patients, especially whether counseling or the ways doctors communicate with patients have an effect on these measures.", "answer": 1}, {"article": "\"So they will be able to make a very personal decision without anyone realizing it,\" he said.\nIf larger clinical trials confirm the results, the test could become standard practice, Patsalis said.\nIt also can identify Down syndrome in the 11th week of pregnancy, early enough for a woman to end her pregnancy if she chooses, Patsalis said.\nDr. Brian Skotko, clinical fellow in genetics at Children's Hospital Boston and a spokesman for the National Down Syndrome Society, said this study has widespread implications for the incidence of Down syndrome.\n\"With our method we identify all normal and all Down syndrome [pregnancies],\" Patsalis said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "No discussion of how this compares with any of the other approaches being studied in this field.", "answer": 0}, {"article": "\"The work by [first author] Price et al.\nstrongly supports the basic rationale being pursued at Sirtris, which focuses on the development of small-molecule compounds that directly activate the enzymatic activity of SIRT1 as a new therapeutic approach to many diseases of aging,\" Vlasuk wrote in an email to the journal.\nTesting the effect of resveratrol on SIRT1 in mice was difficult, Sinclair said.\nBut tests of muscle tissue in mice with a normal SIRT1 gene that were given resveratrol found that the substance boosted mitochondrial function.\nIn 2010, according to news reports, the company, which is owned by GlaxoSmithKline, halted clinical trials of resveratrol, but Sinclair said the company continues to develop improved synthetic molecules.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did mention some previous research on the issue:\n\u00a0 \u201cWhile previous studies have also suggested that resveratrol may have anti-aging properties, the precise mechanism of resveratrol has been controversial. Several studies, including work with yeast, worms and flies, have found that resveratrol acts on a class of seven genes known as sirtuins and, in human cells, SIRT1 in particular.\u201d", "answer": 1}, {"article": "Stroke.\n\u201cThe recovery some patients showed was not just minimal, it was significant,\u201d said Steinberg, who has researched stem cell therapies for more than 15 years.\nThey hypothesized that injecting stem cells into the brains of chronic stroke patients would increase their survival rates.\nIn Steinberg's study, it did not \u201ccause problems by differentiating into unwanted tissues or forming tumors.\u201d And even when the stem cells came from an unrelated donor, the participants did not experience a strong immune reaction.\nRecently, researchers from the Stanford University School of Medicine have made it their mission to improve these outcomes.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We\u2019ll\u00a0give this a Satisfactory rating here because the article does make the point that the stem cell therapy trial in question does demonstrate safety and some efficacy; and it also notes\u00a0that the benefits were detected regardless of the severity, duration, or location of the stroke in the test population.\nAnd it does well by mentioning that previous research showed the stem cells used can \u201ctreat\u201d brain cell damage caused by loss of oxygen, essentially what happens in an ischemic stroke. The article could have done better by saying whether that past research was done in lab-grown cells or in animals.", "answer": 1}, {"article": "Angioplasty, which uses a balloon to open blocked arteries, has been a popular alternative to bypass surgery in part because it brings less trauma to the patient.\nUsing robotics to bypass major blocked arteries and putting stents in other blocked arteries is gaining some currency, Rabbitt said, although few surgeons have come close to Srivastava's familiarity with the robot.\nSrivastava said it is true that the normal sense of touch is missing from robotic work, and that is a shortcoming, but it can be overcome with practice.\n\"The exactness of bypass surgery is so high that many people are reluctant to do it without tactile as well as visual feedback.\"\nEven though they cost, on average, $1.5 million, the robot systems are gaining popularity.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "While the article implies that use of the robotic device for heart bypass surgeries is rare, insufficient data is provided to help readers understand how rare it is. Since the report says the machines have been in wide use most of this decade, it should have been clearer about how many hospitals use the machines for bypass surgery, what else they use them for and\u00a0which patients are considered best candidates for it. Nonetheless, we\u2019ll give the story the benefit of the doubt on this criterion.\u00a0 ", "answer": 1}, {"article": "The researchers evaluated 140 patients aged between 60 and 87 who underwent surgery under propofol-induced general anesthesia at the Central Institute of Hospital das Cl\u00ednicas, FM-USP's teaching hospital, in most cases for removal of gallstones.\n\"Little is said about rehabilitation or ways of helping patients recover pre-operative cognitive function.\"\nBefore that, older patients were rarely subjected to major surgery, and significant research in this field has only been conducted for approximately 15-20 years.\n\"The results reinforce recent evidence of the importance of avoiding deep anesthesia,\" Carmona said.\n\"The causes of and risk factors for POCD are still being discussed,\" she said.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "It\u2019s clear from the release that this is a new (and, ergo, novel) approach addressing a well-established problem.  ", "answer": 1}, {"article": "The acupuncture recipients reported more energy and even an increased sex drive, compared with women using Effexor.\nBut in this study, the patients in the \u201creal\u201d acupuncture group all received needles inserted in the same way.\n\u201cThere is a body of literature that argues that the whole approach to studying acupuncture doesn\u2019t lend itself to the Western reductionist scientific method.\u201d\n\nBut the study\u2019s lead author, Dr. Maria E. Suarez-Almazor, notes that the sham treatment was developed with the help of trained acupuncturists.\nBut that result has been called into question because the patients in the sham group probably figured out they were not getting the real thing.\nThe researchers, who published their findings in Archives of Internal Medicine, speculated that inserting needles in or around an area of pain may have caused a \u201csuper placebo\u201d effect, touching off a series of reactions that changed the way the body experienced pain.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "      \n\n\n \n\n \nThe article stated in the first sentence that acupuncture has a 2000-year history.\n ", "answer": 1}, {"article": "\"What we wanted to find out was: 'Would cooling the surface of the brain of insomnia patients result in lower metabolism and improved sleep?\nThe cooling cap was, however, associated with an increased amount of slow-wave sleep -- or the deepest, restorative portion of sleep, the researchers reported.\nPrevious research has shown that the brains of people with insomnia are \"hyperaroused\" and have a higher brain metabolism in the frontal lobes, which helps explain why they have trouble drifting off to sleep and staying asleep, said study co-author Dr. Daniel Buysse, a professor of psychiatry and clinical and translational science at University of Pittsburgh School of Medicine.\nDr. William Kohler, medical director of the Florida Sleep Institute, said the concept was exciting and worth further research in larger studies that include body temperature measurements and brain imaging tests.\nBecause this study was extremely small and presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal and confirmed in larger studies.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "A quote from an independent researcher establishes that this is not a totally new field of research:\u00a0 \u201cwe do know from many previous studies that as the body core temperature cools, our sleep improves, and with warming of the core temperature, we have more restless sleep.\u201d", "answer": 1}, {"article": "SIR Annual Scientific Meeting, March 17-22, 2018.\n\"This minimally invasive treatment offers patients a novel way to directly and indirectly attack the cancer cells.\"\nAs part of the study, researchers will follow patients for up to two years, and new trials to investigate the effectiveness of the drug in treating advanced cancer in the liver are being planned.\nResearchers found that talimogene laherparepvec (T-VEC)--a genetically modified version of the herpes virus--can be safely administered into active cancer in the liver and stimulate the immune system to destroy cancer cells throughout the body.\nPatients were given escalating doses of T-VEC, up to the maximum FDA-approved dose for melanoma.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The lead researcher was quoted saying, \u201cThis minimally invasive treatment offers patients a novel way to directly and indirectly attack the cancer cells.\u201d\nThe idea of deploying natural occurring viruses to selectively kill cancer cells has been around for decades but research has taken off in recent years, according to a 2016 paper. It states: \u201cMany clinical trials using T\u2010VEC are currently performed worldwide by the (Amgen) pharmaceutical company in order to expand its application and also to expand countries for marketing.\u201d", "answer": 1}, {"article": "Neurosurgeons performing EDAS reroute arteries from the scalp and the membranes that cover the brain and place these arteries under the skull near areas of the brain at risk of stroke.\nGonzalez said his team is working with the stroke prevention working group of the National Institutes of Health to develop a proposal for a Phase III randomized clinical trial across multiple institutions to further test the effectiveness of EDAS as compared with intensive medical management.\nWhile this Phase IIa trial selected patients from previous studies as the control group, the Phase III study would enroll new ICAD patients for both the control and experimental groups, he explained.\nTwo of the EDAS patients had small wound openings that required additional surgical interventions, but there were no intracranial hemorrhages or other serious adverse events, the researchers reported.\nThe trial, led by Nestor R. Gonzalez, MD, professor of Neurosurgery and director of the Neurovascular Laboratory at Cedars-Sinai, enrolled 52 patients with severe brain atherosclerosis, also known as intracranial atherosclerotic disease, or ICAD, who showed symptoms of either a recent stroke or a mini-stroke, called a transient ischemic attack.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release quotes an expert stating that \u201cThis clinical trial moves us significantly closer to preventing strokes and death in high-risk populations.\u201d\u00a0 But is that really the case when the results show lack of statistical significance?\nThis release and potential news coverage of it could lead to false hopes by patients who have had a TIA or stroke\u00a0and are looking for any available therapy to reduce their risk of recurrence.", "answer": 0}, {"article": ".\nThis study would also suggest that humans lost something when we rid ourselves of the microbes and parasites that had evolved alongside us for tens of thousands of years.\nThe study is the latest from a surprising field of research into the potentially positive sides of parasites, one of the most maligned groups in the animal kingdom.\nThe doctor wanted to know whether there might be a connection between the dramatic success of deworming programs around the world and the rise of immune system problems like asthma and celiac disease.\nAnd because of the risks associated with parasites, going around infecting people isn't a viable treatment option.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Research about therapeutic use of hookworms and other parasitic worms (helminths) has been around since the 1990s, although it has entered into the public consciousness within the past five years at most. So in one sense, the material in this article is novel. The beginning of the story describes the genesis of this line of research in questions about the\u00a0connection between the dramatic success of deworming programs around the world and the rise of immune system problems like asthma and celiac disease. However, the article makes no mention of multiple previous and ongoing studies investigating the effects of \u201cworm therapy\u201d on auto-immune diseases like Crohn\u2019s disease, multiple sclerosis, and asthma. The idea that parasites may play a role in the development of the human immune system is still surprising for most of us, but not as novel as this report on the findings of a single research group would suggest\u2013just a few months ago we reviewed an NPR story on worms for allergies. The article should have provided more context.\n\u00a0", "answer": 0}, {"article": "\"What we found is that kids get home from school around 4 p.m.\nThe researchers conclude that afterschool programs and schools can replace energy dense, unhealthy snacks with peanuts to provide a healthier alternative for children (researchers in the study ensured students did not suffer from nut allergies).\nThe study acknowledged that snacking is more common during the adolescent years and that the unhealthy eating habit can lead to an unhealthy weight.\nFollowing the 12-week intervention, students spent 12 more weeks maintaining the healthy snacking habit.\nThe snack was administered after school as students were boarding the school bus to go home.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release doesn\u2019t make clear what\u2019s novel about the research. Prior to this research it was already widely accepted that choosing healthy snacks (along with physical activity) over unhealthy ones is helpful in preventing weight gain.", "answer": 0}, {"article": "The Hass Avocado Board (HAB) is an agriculture promotion group established in 2002 to promote the consumption of Hass Avocados in the United States.\nClinical studies are currently underway to investigate the relationship between avocado consumption and risk factors for heart disease, diabetes, support of weight management and healthy living.\"\nOn the heels of this advice, a new meta-analysis (considered the best evidence and an unbiased overview of the body of knowledge on a specific topic), published in the Journal of Clinical Lipidology, adds to the growing body of research that supports the use of avocados in lieu of solid fats (and foods that have higher saturated fat content) to significantly change lipid profiles.\nIn 2010, HAB established a nutrition research program to increase awareness and improve understanding of the unique benefits of avocados to human health.\nThe research, \"Impact of avocado-enriched diets on plasma lipoproteins: A meta-analysis,\" conducted at the University of the Pacific and independently funded , looked at 10 unique avocado studies with 229 participants, assessing the impact of avocados on cholesterol levels.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release makes it clear that the study is an analysis of previous research and that it lends further support to the idea that avocados may be beneficial to one\u2019s diet. It\u2019s evident that the \u201cnews\u201d here is the study, and that the idea that avocados lower cholesterol isn\u2019t novel in and of itself.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070311/19clot.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of the diagnostic method and the treatment were accurately reported.", "answer": 1}, {"article": "Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Alternative and Complementary Therapies, Medical Acupuncture, and Journal of Medicinal Food.\nThe study design and results, which suggest further controlled studies of this intervention approach in ASD, are published in the Journal of Alternative and Complementary Medicine (JACM), a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.\nCoauthors Lana Warren, EdD, OT/L and Patricia Rao, PhD, Kennedy Krieger Institute, Baltimore, MD, and David Paton, DAc, LAc, Starting Point Acupuncture and Health Services, Catonsville, MD, identified the most positive outcome of the study as the high compliance rate, with all parents of the children ages 3-10 completing the intervention.\nIn the article entitled \"A Pilot Observational Study of an Acupressure/Acupuncture Intervention in Children with Autism Spectrum Disorder,\" most parents reported that the intervention had a positive impact on their relationship with their child.\nThe Journal of Alternative and Complementary Medicine (JACM) is a monthly peer-reviewed journal published online with open access options and in print.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Acupuncture research related to ASD is not new. Here\u2019s a systematic review of the relevant literature from 2011, and another from the same year. The Cochrane review, among the collection of studies included in the reviews above, concludes that: \u201cWe need high quality trials of larger size and longer follow-up as the evidence base at present has many limitations.\u201d\nBut the study described here tackles the subject in a new way, that of the feasibility of being able to complete therapy.\u00a0 Prior studies haven\u2019t shown that it\u2019s feasible for families to commit to longer term acupuncture therapy.", "answer": 1}, {"article": "Kite Pharma is racing to get the first FDA approval of an experimental gene therapy to fight cancer.\n\nAn experimental gene therapy that turns a patient\u2019s own blood cells into cancer killers worked in a major study, with more than one-third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday.\n\nIn all, 82 percent of patients had their cancer shrink at least by half at some point in the study.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story immediately states\u00a0that this\u00a0is an experimental therapy and that there are no approved gene therapies currently available in the United States. It would have helped readers to know that over a dozen medical centers across the country are entering their second year of Phase I or II trials with CAR-T.", "answer": 1}, {"article": "The amygdala processes incoming emotionally salient stimuli, whereas the prefrontal cortex, as the executive center of the brain, decides whether the incoming stimuli are noteworthy.\nThe initial results demonstrate that the efficacy of this digital therapeutic is comparable to drug therapy, with a highly favorable safety profile.\nMSIP is responsible for the full spectrum of commercialization activities required to bring the Icahn School of Medicine's inventions to life.\nThis technology illustrates our strengths in translating health care discoveries from the academic setting into industry, and ultimately to the patients that will benefit from them.\"\nThis treatment was developed at the Icahn School of Medicine at Mount Sinai by Brian Iacoviello, PhD, an Assistant Professor of Psychiatry who is Director of Scientific Affairs for Click Therapeutics, and Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean and Professor of Psychiatry, Neuroscience, and Pharmacological Sciences.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release establishes the\u00a0novelty about this technology. Although we think this could have waited until a large, randomized study had been completed\u2013and peer-reviewed\u2013before they publicized the work.", "answer": 1}, {"article": "Genomic Health Inc. has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new-generation drugs or rely on much cheaper traditional chemotherapy to improve their chances for survival.\n\nThe test, developed by closely held Epic Sciences Inc., San Diego, detects a mutation associated with a poor response to two new drugs, Xtandi from Medivation Inc. and Astellas Pharma Inc. of Japan, and Zytiga from Johnson & Johnson.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Since AR-V7 is not currently used as a biomarker for treatment of advanced prostate cancer, it is clear enough to the reader that this is a new approach.\nAn important point that is only mentioned in passing\u00a0is that the test is a \u201cliquid biopsy.\u201d Liquid biopsies have\u00a0often been hyped as a revolutionary new approach to diagnosing cancer without invasive procedures. However, due to questions over sensitivity and reliability, they have been controversial and are yet to become commonplace in clinical practice, so readers might have benefited from a little more context on this point.", "answer": 1}, {"article": "Myo-inositol is also found in fruits, beans, grains and nuts, although Bild said the finding does not necessarily explain why people who eat more of these foods have a lower risk of cancer in general.\nPI3K had long been suspected in lung cancer.\nAnd, they said, a natural supplement derived from food that is being tested to prevent lung cancer appears to halt the precancerous changes.\nAnd the second group was taking the natural supplement, myo-inositol, to try to prevent lung cancer.\n\u201cEven in normal cells or premalignant cells prior to cancer development we see this pathway being turned on,\u201d said Andrea Bild of the University of Utah, who worked on the study published in the journal Science Translational Medicine.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "       \n \nThe story indicates that PI3K had \"long been suspected in lung cancer.\" \n ", "answer": 1}, {"article": "Toenail fungus causes nails to become thick, yellow and brittle in a way that looks pretty ugly and can be painful.\n\u201cI\u2019ve had patients come in who have had laser procedures and not seen long-term success.\u201d\n\nFirestone also says that over-the-counter antifungal nail creams and ointments rarely work because they can\u2019t penetrate the nail root.\nIn this case, there is a chance.\u201d\n\nEven John Strisower, the founder of PinPointe USA, says patients should expect at least a minimal reinfection within five years after laser treatment.\nThe treatment, in which the podiatrist aims a laser beam at the patient\u2019s toenails to kill the organisms that cause the fungus, costs about $1,000 and is not covered by insurance because it is considered an aesthetic procedure.\nPractitioners have been using other lasers on toenail fungus since about 2009.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There are many claims of success in this story but no proof that the treatment is truly novel or that it truly represents \u201chope.\u201d Lasers have been used off label to treat toe nail funges for several years, as the story notes.", "answer": 0}, {"article": "To make sure it works, though, the Centers for Disease Control and Prevention says doctors need to do a number of things:\n\u2022 Prescribe Truvada only for men at high risk of getting infected \u2013 that is, only for men who have sex with men, those who have multiple sex partners, and those who live in areas where there's a lot of HIV circulating.\nIt's the first time anybody's shown that taking a pill can prevent HIV \u2013 and it was the first new weapon against HIV unveiled in many years.\nThe pill, called Truvada, is already on the market for treating HIV infections.\nAmong those whose tests showed they really did take it every day, the risk of HIV infection was 92 percent lower than those not on the drug.\nWhen researchers tested the blood of patients for traces of Truvada, they found many who claimed to have taken the pill regularly weren't telling the truth.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story stated, \u201cIt\u2019s the first time anybody\u2019s shown that taking a pill can prevent HIV \u2013 and it was the first new weapon against HIV unveiled in many years.\u201d", "answer": 1}, {"article": "On the other hand, it is unclear whether a donor could potentially transmit a disease to the recipient in the process.\nThe phase I results from 53 patients are not definitive proof that the treatment is effective, but do suggest so, Hare said.\nThis method of intravenous injection means that the procedure theoretically could be performed in a doctor's office or clinic, increasing the accesibility to patients, Karp said.\nAn area of improvement would be making the stem cell treatment more efficient, he said.\nThere was no change or increase in side effects in treatments getting higher doses of cells, but it seemed that the treatment was more effective -- at least in terms of reducing electrical problems -- in the high dose group, he said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not make false claims for the procedure\u2019s novelty. See he criterion \u2013 \"Compare the new approach with existing alternatives\" \u2013 below.", "answer": 1}, {"article": "Find more information at www.uab.edu and www.uabmedicine.org.\nThere are more than 30-plus new dry eye basic, translational and clinical studies being funded by the NEI/National Institutes of Health to further explore these lipids and proteins, with more than 50 papers being published monthly.\n\u201cIt is critical for eye care professionals to have a dialogue with patients who report symptoms because dry eye can be a progressive ocular surface disease.\u201d\n\nThe twice-daily eye drop solution of 5 percent lifitegrast ophthalmic solution is the only prescription eye drop indicated for the treatment of both signs and symptoms of dry eye, and it is the first new dry eye prescription drop approved in the last 13 years.\nKelly Nichols, O.D., Ph.D., a dry eye expert and dean of the University of Alabama at Birmingham School of Optometry, conducted research studies for the parent drug company to explore the efficacy and safety of lifitegrast in treating this eye condition that affects more than 16 million adults in the United States.\nSpecialty testing for dry eye is performed at the Dry Eye Relief Clinic at UAB Eye Care, in the School of Optometry.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release claims that the product \u201cis the only prescription eye drop indicated for the treatment of both signs and symptoms of dry eye, and it is the first new dry eye prescription drop approved in the last 13 years.\u201d That\u2019s partly true, as the fact-checking site PolitiFact might say.\nThere are other prescription and over-the-counter eye drops available for treating the signs and symptoms of dry eye. Restasis, a drug that stimulates tear production, was approved in 2003, so the claim that Xiidra is the first prescription drug \u201capproved in the last 13 years\u201d for dry eye is true, to our knowledge.", "answer": 0}, {"article": "One of the most frustrating aspects of brain injuries is that they can be difficult to diagnose; emergency rooms can sometimes miss subtle symptoms, leading to improper treatment and potentially catastrophic consequences. Now, researchers are close to identifying so-called biomarkers that may soon make it possible to pinpoint brain injuries with a simple blood test.\n\nPresence of these biomarkers\u2014proteins produced by an injured brain\u2014could end up determining the future treatment of the estimated 1.4 million athletes, car-crash...", "question": "Does the story establish the true novelty of the approach?", "explanation": "Though the story could have commented about other biomarkers besides the Banyan one(s), it\u2019s clear that this is a novel diagnostic test.\u00a0", "answer": 1}, {"article": "This page either does not exist or is currently unavailable.\n\nFrom here you can either hit the \"back\" button on your browser to return to the previous page, or visit the ABCNews.com Home Page. You can also search for something on our site below.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Examined a new use for a \nclass of medications (statins). ", "answer": 1}, {"article": "Dr. Scolnick has not seen the results of the Novartis trial, but was told of them and concluded that if the drugs work in fragile X, \u201cthere\u2019s nothing to say that they won\u2019t work in some cases of broader autism-spectrum disorders.\u201d\n\nThe roots for the Novartis results began in 1982 when Stephen T. Warren, then a graduate student in genetics at Michigan State University, was looking for a job and something to research.\nOne reason for the euphoria surrounding the Novartis trial is that it was seen as an especially difficult test of the drug\u2019s effects.\nSure enough, mice, fish and fruit flies that through genetic engineering were made to have fragile X seemed to become normal when given Dr. Bear\u2019s compound.\nAnd despite going to some of the best hospitals in the country, four years would pass before Andy\u2019s condition was properly diagnosed.\nThe Novartis compound is a member of the same drug family.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This drug does by all accounts represents a novel approach to the treatment of fragile X syndrome. \u00a0", "answer": 1}, {"article": "\"In the United States, 70 percent of smokers want to quit, but quitting is extremely difficult.\nChrono's first application is in smoking cessation, enabling smokers to overcome the world's deadliest addiction.\nThe data were presented today at the Society for Research on Nicotine & Tobacco's 22nd Annual Meeting.\n\"Gums and patches are designed to help manage cravings, but they are only 5 to 9 percent effective.\nChrono's team is developing the first wearable transdermal drug delivery device that optimizes drug dosing, is embedded with sensor technology to track usage and is connected via Bluetooth to an evidence-based smartphone application that delivers real-time personalized behavioral support to keep users on track to achieve their goals.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This device provides nicotine in a novel way by administering it according to Chrono\u2019s \u201cpeaks and troughs\u201d profile and combining nicotine delivery with smartphone app monitoring. The release establishes this but doesn\u2019t overstate things.", "answer": 1}, {"article": "Gluck et al.\nObesity 4 Nov.\n\nNIDDK Research Clinical Psychologist Marci Gluck, Ph.D., is available to comment on this study.\nMore study is needed to confirm the safety and effectiveness of tDCS for weight loss.\nThen for three days, they unknowingly received either active or sham (fake) transcranial direct current stimulation, or tDCS.\nOn each visit, the participants ate a weight-maintaining diet for five days.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "It\u2019s clear this is being studied at a federally funded obesity center and that the approach of measuring calorie intake after stimulation is new.", "answer": 1}, {"article": "\"My impression is, even with the newer band, the results are not significantly better,\" he says.\nBut a spokesman for the company that manufactures Lap-Band says the study is flawed.\nEven so, a majority of the patients in their small study said they were satisfied with the procedure.\nThe critics also point out that both the device itself and the expertise of surgeons placing it have improved greatly since the patients in the study had their bands placed, in the years 1994 through 1997.\nBut some, including the manufacturer of the Lap-Band -- used in a technique called laparoscopic adjustable gastric banding -- take exception to the study, criticizing the small sample size and the number of patients lost to follow-up.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was clear that it was not reporting on a new or novel treatment but rather was reporting on the long-term outcomes presented in a recent research paper.", "answer": 1}, {"article": "This measure of metabolic health is called \u201cinsulin sensitivity,\u201d and it is one of many metabolic functions that goes awry in people with obesity. In those who develop type 2 diabetes, sensitivity to insulin becomes so impaired that the body is tricked into believing less insulin is needed, and it pares back its production. The insulin-producing cells in the pancreas will often atrophy and die in response. As a person\u2019s insulin production declines, an external supply of insulin is needed to control blood sugar and deliver fuel to muscles and organs.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes clear that the novelty of this study is that it introduces a new brain area (the nucleus accumbens rather than the hypothalamus) as having regulatory control over metabolism.", "answer": 1}, {"article": "\"It's like 'Star Trek.'\nToday, the artificial retina is primarily for sufferers of retinitis pigmentosa, but it could expand to other diseases, like dry age-related macular degeneration, Mech said.\nAnd while some patients like Campbell do well with the implant, there are some who struggle.\nAnd just recently, during a vision test, Campbell was able to correctly identify a sequence of letters for the first time in decades.\nDevices with 100 and 1,000 electrodes are in production, and the hope, Mech said, is that more electrodes will mean more-detailed vision.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story incorrectly implies novelty of this device. \nMany companies and research teams worldwide are pursuing artificial retinas; some others\u2019 technologies are more technically advanced. Indeed, there is a federal government program to support the many development efforts. \nOther treatments to restore vision are being researched actively.\u00a0\nOddly, one of them was featured in a September 2009 story that appears on\u2026CNN\u2019s website. ", "answer": 0}, {"article": "Observers measured the symmetry of their smiles, checked for drool and listened to them read sentences.\nThose patients would be expected to have lingering pain, and should not get Oraverse, Dr. Moore said.\nNovalar and some dentists who advise the company said it might be useful for children, who can injure themselves by biting their lip or tongue without knowing it.\nIn the clinical trials there were no serious side effects, Novalar said.\nDr. Papas, an adviser to Novalar and an investigator in its clinical trials, said she thought the drug would appeal especially to those receiving cosmetic dentistry \u201cwho like to look good when they leave the dentist\u2019s office.\u201d\n\nNovalar said its surveys showed great interest in the product among consumers and among dentists, some of whom said they would mark up the price of the drug as a source of profit.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article does a good job of explaining that the drug itself has been in use for a long time to treat severe hypertension, but that its use to reverse the effects of dental anesthesia is novel. ", "answer": 1}, {"article": "It's a barrier between enamel and the soft tissue that contains all the blood vessels and cells,\" Celiz explained.\nInstead of the current dental materials used on fillings, which are toxic to cells, the new approach harnesses stem cells instead.\nThough the work is still in its early stages, and has not yet been tested in people, the scientists won an award from the Royal Society of Chemistry for their idea: regenerative dental fillings.\nIf successful, a treatment like this could someday offer significant benefits for millions of dental patients each year.\n\"We're trying to provide an alternative material, an alternative therapy,\" he said, because the current method involves the dentist removing all of the infected pulp tissue, \"scraping it out, and it can be very painful.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story suggests that this research is indeed new. \u00a0This is indeed not the case, stem cells have been studied for dental applications for years. \u00a0A group in Japan has been developing\u00a0a stem cell based therapy for dental caries that\u00a0has progressed in 2013 to animal studies.", "answer": 0}, {"article": "Foods to avoid\n\n Dairy: Milk, ice cream, yogurt, cottage and ricotta cheeses (except for lactose-free versions)\n\n Fruits: Apples, peaches, pears, watermelon, cherries, figs\n\n Vegetables: Garlic, onions, leeks, asparagus, cauliflower or large servings (more than \u00bd cup) of broccoli and Brussels sprouts\n\n Grains: Wheat (except in sourdough bread), rye, barley\n\n Legumes and nuts: Cashews, kidney beans, soy beans and soy milk\n\n Sweeteners: Honey, fructose, xylitol, agave syrup\n\nFoods to include \n\n Dairy and dairy substitutes: Kefir, almond milk, coconut milk\n\n Fruits: Bananas, blueberries, grapes, oranges, strawberries\n\n Vegetables: Carrots, green beans, bell peppers, potatoes, tomatoes\n\n Grains: Rice, oats, gluten-free bread (but check labels for high-FODMAP ingredients)\n\n Legumes and nuts: Peanuts, pecans, walnuts\n\n Sweeteners: Cane sugar, aspartame, stevia\nIt\u2019s not known if the diet leads to any nutritional deficiencies or keeps working in the long run \u2014 especially for patients who get little support from doctors or dietitians.\nBut few dietitians are trained in the diet, and insurers typically do not cover the visits, Lacy notes.\nWhen patients do make their way to Kate Scarlata, a Boston area registered dietitian who specializes in the diet, the first thing she tells them is that it \u201cis a dietary experiment.\nIf giving up some foods might lessen that misery, many people are game, she says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes the case that the diet is a different approach than the alternatives (medications, probiotics, fiber), but it also makes it clear that this diet has been around for awhile. This is a trend story on this type of eating, rather than a look at a specific study.", "answer": 1}, {"article": "Primary pulmonary hypertension (PPH), a rare fatal lung disease, has been reported in patients who had taken a combination of phentermine and fenfluramine or dexfenfluramine for weight loss.\nThe limited usefulness of agents of this drug class (anorectics), including Lomaira, should be measured against possible risk factors inherent in their use.\nThese are not all of the potential side effects of phentermine.\nThese are not all of the potential side effects of phentermine.\nDosage should be individualized to obtain an adequate response with the lowest effective dose.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "We\u2019ll give this release the benefit of the doubt for this category. Lomaira isn\u2019t a new drug, this is only a new dosage that may be more effective for some patients and their prescribing physicians.\u00a0 As such, the novelty of this release is minimal at best.", "answer": 1}, {"article": "AMD, the No.\nThese provocative results were then confirmed in a much larger data set of 87 million patients where similar results were observed and the study expanded to include prevention and delay of \"wet\" AMD, the most devastating form of the disease.\nThe next step in this research is to perform a clinical trial to determine the ability of this drug to prevent AMD.\n\"Showing that L-DOPA causes this protective effect will require further investigation, but if confirmed, could lead to new drugs or combination therapies for AMD that target DOPA-responsive cells in the retina.\"\n\"In the end, L-DOPA may not be the drug that ends the disease but the pathway identified is likely to be a key observation as the search for a cure continues.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The idea that an established drug might be effective against a disease other than what it was intended to treat is novel enough to justify a release touting the findings of an acceptable study.\u00a0And the release makes clear that this study was prompted by earlier studies in mouse models that supported a role for L-DOPA in AMD.", "answer": 1}, {"article": "Food sources of vitamin E include wheat germ, nuts such as almonds and hazelnuts, vegetable oils such as sunflower and safflower oils, and some green vegetables, such as spinach and broccoli.\nIt is unlikely that people could get too much vitamin E from food.\nExperts advise that adults consume no more than 1,000 mg of vitamin E per day.\nAnd it supports findings from some previous research that dietary vitamin E, in particular, might be related to a lower risk of dementia.\nThe findings, reported in the Archives of Neurology, do not prove that vitamin E itself protects the aging brain.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The idea that vitamin E and other antioxidants might protect against dementia is not new, and the story doesn\u2019t suggest that it is.", "answer": 1}, {"article": "Fish like salmon, herring and sardine are a common source of EPA-DHA, while ALA is found in vegetables including soybeans, flax seeds and walnuts.\nDaan Kromhout of Wageningen University, who led the study, told the European Society of Cardiology the lack of efficacy might reflect the good background drug treatment patients were receiving, with 85 percent on cholesterol-lowering statins, as well as blood pressure and blood-thinning tablets.\nUnilever, whose margarine brands that contain omega-3 include Flora and I Can\u2019t Believe It\u2019s Not Butter, said the lack of benefit seen with EPA and DHA was surprising, considering the weight of evidence published to date.\n\u201cThe results indicate that more investigation is required into the efficacy of vegetable omega 3, but do not question the current authoritative dietary recommendations and advices for omega 3 intakes on which our products are based,\u201d the company said in a statement.\nThe margarines used in the study were developed for the researchers by food and consumer goods giant Unilever.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0Although the product being tested was indeed novel as the story indicated, the story was reported from the standpoint of possible impact the results of the study might have on dietary recommendations or the use of n-3 fatty acid supplements.", "answer": 1}, {"article": "\"Now they tell me, 'You never say 'What?'\nUnlike a hearing aid, which amplifies sounds, Esteem is a prosthetic inner-ear stimulator.\nThe implant is permanent.\n\"This really fills a need for adults with moderate to severe sensorineural hearing loss,\" Marzo said.\nOften, it meant only being able to do one thing at a time, explained the mother of three young children.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "According to the FDA, \u201cEsteem is the first totally implantable hearing system used to treat moderate to severe hearing loss caused by a defective inner ear function.\u201d The article could have made this fact clearer,\u00a0 but states that this implant, a prosthetic inner-ear stimulator, differs from a hearing aid, which \u201camplifies sounds.\u201d", "answer": 1}, {"article": "The researchers believe that adding probiotics to the peanut allergens may be important in improving the children\u2019s tolerance to the food, but Dr. Anna Nowak-Wegrzyn, an associate professor of pediatrics at Icahn School of Medicine at Mt.\nBut the new findings provide even more evidence that using peanuts to treat peanut allergy, and to re-train the immune system to be less allergic, can be effective.\n\u201cThe question for me would be if there is a difference between patients who were treated with [both] immunotherapy [in the form of low doses of peanuts] and probiotics, and those who were treated with just immunotherapy.\u201d\n\nThat may have to wait for another study.\nThe study, published in the journal , follows up on children enrolled in an earlier study of an immunotherapy treatment, which combined probiotics with small doses of peanuts that were designed to gradually train the children\u2019s immune systems to accept the peanut allergen rather than treat it as something foreign.\nThe results are encouraging, allowing the children who were treated to eat peanuts without fear of an allergic reaction.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty here would appear to be that this is a long-term follow-up to a study that used probiotics in conjunction with oral immunotherapy for peanut allergy. That\u2019s inferred here, rather than stated explicitly, which isn\u2019t necessarily a deal breaker. But after talking about what impact probiotics might have had in the treatment results, the story ultimately tells readers that figuring out what sets this research apart \u201cmay have to wait for another study.\u201d Having to include language like that is likely a sign to steer clear of a headline like this one: \u201cNew Therapy May Cure Kids of Peanut Allergy.\u201d Then again, the new therapy may not.", "answer": 0}, {"article": "Because atrial fibrillation increases the risk for stroke, people with the condition are often prescribed blood thinners (also known as anticoagulants) to prevent blood clots that can cause a stroke.\nWhen the researchers focused on people who continued to take the drugs, they found an even larger reduction (48 percent) in the risk for dementia.\nThe findings strongly suggest that blood thinners reduce the risk for dementia in people with atrial fibrillation, but proving that would not be possible, the Swedish researchers said.\nHowever, the findings show that people with atrial fibrillation should start taking blood thinners as soon as possible after their diagnosis and continue to take the drugs, Friberg noted.\nThey also found that the sooner people started taking blood thinners after their diagnosis of atrial fibrillation, the lower their risk for dementia.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it sound like the anticoagulant-dementia risk connection is a brand new discovery. However, the study that\u2019s the basis of the story notes that numerous researchers have already examined this hypothesis and come to conflicting conclusions. The story should have indicated what\u2019s new and different about this study compared to the previous ones, if anything.", "answer": 0}, {"article": "Performed through the urethra, an urologist uses the UroLift System to push aside the obstructive prostate lobes and positions small, tailored permanent UroLift implants to hold the prostate lobes in the retracted position.\nPatients recover from the procedure quickly, and return to their normal routines with minimal downtime.\nThe UroLift System provides an alternative to tissue removing surgery for the treatment of an enlarged prostate.\nAdverse reactions associated with UroLift System treatment were comparable to other minimally invasive surgical therapies as well as standard cystoscopy.\nMost symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release offers some details on how this system is different from drugs and other surgical type treatments, so this merits a passing grade.", "answer": 1}, {"article": "Malignant pleural mesothelioma is a rare and aggressive cancer that represents about 90 percent of all malignant mesothelioma cases.\nThe study, published this month in The Lancet Oncology, is the first to show a positive impact from checkpoint inhibitor immunotherapy drugs on this disease.\nThere are multiple studies going on right now to confirm these findings, which the authors note is a necessary step before the drug can become a standard second-line therapy.\nThose studies are expected to launch later this year, including two at Penn.\nFourteen patients passed away during the study, while four were still undergoing treatment as of the study's writing.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release states that the study \u201cis the first to show a positive impact from checkpoint inhibitor immunotherapy drugs on this disease.\u201d We\u2019ll give the benefit of the doubt here since the study may be the first of its kind, but the phase 1b trial set out to show safety, not effectiveness.  ", "answer": 1}, {"article": "LONDON (Reuters) - Scientists in Britain have developed a type of HIV test using a USB stick that can give a fast and highly accurate reading of how much virus is in a patient\u2019s blood.\nBut in some cases the drugs stop working - sometimes because virus has developed resistance to them - and the first sign of that would be a rise in a patient\u2019s so-called \u201cviral load\u201d.\nThe device, created by scientists at Imperial College London and the privately-held U.S. firm DNA Electronics, uses a drop of blood to detect HIV, then creates an electrical signal that can be read by a computer, laptop or handheld device.\nAny HIV in the sample triggers an acidity change, which the chip transforms into an electrical signal.\nIt could be particularly useful in remote settings to help HIV patients manage their treatment more effectively, since current tests to detect virus levels take at least three days and involve sending a blood sample to a laboratory.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes the exploratory nature of the test and its speed, at least relative to a standard (though unnamed) lab test, hinting at its novelty.", "answer": 1}, {"article": "\"We were worried that there'd be too much scar tissue in the retina itself to be able to deliver the material to the correct spot,\" he said.\nBut the most dramatic result brought Manuela one step closer to her dream of reading.\n\"She said 'no problem,' which was probably oversimplified.\nAfter her surgery the difference was dramatic.\nTwo months later, it was time for follow-up assessments.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "While making it seem like the patient profiled was the first to receive this treatment, the same group of investigators reported on a patient, Robert Johnson, last year at this time. \u00a0(This was covered by the BBC and in TIME magazine). \u00a0It would have been very interesting to do a follow-up story with this person to see what effect(s), if any, the treatment has had.\nThat said, pursuit of this approach is novel.\u00a0", "answer": 1}, {"article": "Prostate cancer begins when cells in a man\u2019s prostate gland mutate and start to grow uncontrollably.\nThe fusion of MRI and ultrasound imaging technology that we use to accurately identify and diagnose the cancer, combined with the extreme precision of the gold nanoshells in targeting the diseased cells, allows us to be incredibly accurate at obliterating them.\n\u201cThe side effects of current prostate cancer treatments can be extremely traumatic.\nThis procedure is the first in the world that is precise enough to potentially avoid negative ramifications like urinary incontinence or sexual impotency.\nI am excited as we continue tracking the progress of this groundbreaking improvement to prostate cancer care.\u201d\n\nDoug Flewellen, the first patient in Texas to receive the new method of care, says for him, the procedure was a no-brainer.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The novelty of this technique seems to be its major claim to relevance yet the description of its novelty barely passes muster. For example, we don\u2019t learn if gold nanoparticle research is being done for other types of tumors or other types of conditions.", "answer": 1}, {"article": "\"It appears that women who reported taking prenatal vitamins starting three months prior to conception and through the first month after conception seem to have a reduced chance their child will develop autism ,\" says study researcher Irva Hertz-Picciotto, PhD, professor of epidemiology and environmental health at the MIND Institute and Department of Public Health, University of California, Davis.\nExactly why the prenatal vitamins may protect against autism is not clear, she says.\nStill, she says, the finding points to a gene-environment interaction that may possibly help explain some cases of autism.\nThe risk rose if the mothers or the children had a high-risk gene form.\nChildren who had the high-risk COMT gene form were seven times as likely to have autism as children without it whose mothers did take the vitamins.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The association between prenatal vitamins and autism does appear to be a novel and newsworthy finding, as the story suggests.", "answer": 1}, {"article": "Both Florbetapir F 18 and florbetaben help diagnose Alzheimer's by sticking to beta amyloid clumps and emitting radioactivity, which can then be picked up by a PET scan.\nWeiner conducted much of the research leading to Amyvid's approval.\nIt's an early test for those who already have cognitive concerns and who wonder whether Alzheimer's disease may be the cause.\nAnd since no treatment currently works to stem the inexorable progress ofAlzheimer's, who would pay for a costly test to detect it early -- and why?\nAnd some patients may question whether they would want to know that the source of their mental troubles is Alzheimer's disease, said Weiner.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not overstate the novelty of the test or its approval by the FDA.", "answer": 1}, {"article": "And conditions in which the body makes too little insulin or is resistant to its effects \u2014 diabetes, prediabetes, even untreated high-blood pressure \u2014 are associated with an increased risk of Alzheimer\u2019s.\nThat led to the current study, lasting four months.\nThe lower dose seemed more effective than the higher one.\nAnd patients would need a special device to get it deep into the nose.\nCraft wants to test insulin again in a much more extensive study.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story describes the earlier research that laid the foundation for the current study, and does not overstate the novelty of this approach.", "answer": 1}, {"article": "Celgene\u2019s drug Abraxane prolonged the lives of patients with advanced pancreatic cancer by almost two months in a clinical trial, researchers reported Tuesday, signifying an advance in treating a notoriously difficult disease but not as big a leap as some doctors and investors had hoped.\n\n\u201cIt was not the breakthrough we were anticipating,\u201d said Dr. Andrea Wang-Gillam, an assistant professor and pancreatic cancer specialist at Washington University in St. Louis, who was not involved in the trial.\n\nStill, Dr. Wang-Gillam and others said any progress was welcome against metastatic pancreatic cancer, which has defied most treatments, with patients tending to live only about six months after diagnosis.\n\nPancreatic cancer is the fourth most common cause of cancer death, with 38,000 Americans expected to die this year, almost as many deaths as from breast cancer, according to the American Cancer Society. Yet there are only 45,000 new cases of pancreatic cancer a year compared with more than 230,000 new breast cancer cases.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story reported:\n\u201cAbraxane is a novel form of the widely used cancer drug paclitaxel, also known by the brand name Taxol. In Abraxane, the paclitaxel is bound to albumin, a human protein in tiny particles. That is said to enhance delivery of the drug to tumors and reduce side effects.\nAbraxane was approved to treat advanced breast cancer in 2005 and to treat non-small-cell lung cancer in October.\u201d", "answer": 1}, {"article": "At that point, a valve designed to open on its own, allowsthe balloon to empty and be excreted naturally from the body,eliminating the need for endoscopy or another procedure.\nAllurionTechnologies, the manufacturer of the device called Elipse\uf0d4, whichis not yet commercially available, is studyingwhat it says is the \u201cfirst procedureless gastric balloon\u201d inpatients with a body mass index (BMI) of 27 or more.\nThe Agency for Healthcare Research andQuality (AHRQ) reported significant improvements in the safety ofmetabolic/bariatric surgery due in large part to improvedlaparoscopic techniques.\nimmediate pastpresident of the ASMBS and vice-chair, UC Irvine Department ofSurgery and chief of gastrointestinal surgery, who was not involvedin the study said the device is not a permanent solution to weightloss, but has the potential to help those individuals who areoverweight or have obesity and are not candidates for bariatricsurgery.\nInaddition to Dr. Chuttani, study authors of the abstract entitled,\u201cThe First Procedureless Gastric Balloon: A Prospective StudyEvaluating Safety, Weight Loss, Metabolic Parameters and Quality ofLife,\u201d include, Evzen Machytka MD, PhD, Martina Bojkova MD, TomasKupka MD, and Marek Buzga MSc, PhD from the University of Ostrava,Ioannis Raftopoulos MD, Andreas Giannakou MD, and Kandiliotis IoannisMD from the Iatriko Medical Center, and Kathy Stecco MD, Samuel LevyMD, and Shantanu Gaur MD, from Allurion Technologies.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The device manufacturer claims to be the first to deliver a gastric balloon via capsule.", "answer": 1}, {"article": "\"I called the doctor back in and said, 'We're doing the chemo.'\nThe study is ethical, said Dr. Larry Norton of Memorial Sloan-Kettering Cancer Center in New York, because the only women whose treatment will be decided at random are those in a kind of gray area, not women for whom chemotherapy would be a clear benefit or clearly unnecessary.\nThe drawback of that study, Dr. Glick notes, is that it was not a large prospective randomized clinical trial, the gold standard in medicine.\nAnd the recent data indicating that some women can skip chemotherapy are based on an after-the-fact analysis of selected clinical trials.\nIt took two years before the National Cancer Institute and its researchers could even agree on a design for the large new American study that will test the idea that many women might safely forgo chemotherapy.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story describes more tailored (often less) chemotherapy as a newer idea for women who may not benefit as much from more aggressive treatment. This idea is based on recent data regarding the benefit of chemotherapy for tumors fueled by estrogen (ER-positive) and those not fueled by estrogen (ER-negative). ", "answer": 1}, {"article": "Still, the study suggests that brain stimulation \"not only just helps patients who haven't been able to recover from depression, but it seems to be associated with the absence of relapses.\nAnd for now, the research is preliminary, so it's too early to know for sure if the treatment is appropriate to be used for any kind of depression.\nThere are some caveats.\nThe workings of deep brain stimulation as a whole are a mystery, although Mayberg said it may work by changing the brain's rhythms.\n\"I can't think of a scenario where deep brain stimulation would be considered even remotely before medications and ECT were exhausted.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There are no claims of novelty made in the story.", "answer": 2}, {"article": "U.S.-listed shares of Novartis closed up 1.2 percent .\nOn a media briefing following the release of J&J\u2019s trial results, Novartis said it expected the data to have \u201climited clinical relevance\u201d and no impact on plans to expand the Cosentyx label.\n\u201cThese results imply that Cosentyx remains a good option for moderate-to-severe psoriasis patients that want to achieve more rapid skin clearance,\u201d brokerage Jefferies wrote in a note following the results.\nAbout 7.5 million Americans live with plaque psoriasis, of which 20 percent have moderate-to-severe form of the disease, J&J said.\nTremfya, first approved in July 2017 as a plaque psoriasis treatment in the United States, is also being tested as a for psoriatic arthritis and Crohn\u2019s disease.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There are a number of other biologic drugs that treat psoriasis by altering the immune system (this makes sense, because psoriasis is an autoimmune condition), but Tremfya blocks a specific part of the immune system that has not been targeted before. In other words, it is \u201cfirst in class.\u201d The article does not touch on this.", "answer": 0}, {"article": "It is a bold move, but bold moves are what our patients deserve.\"\nThe clinical trial Monoclonal Antibody Sequential Therapy for Deep Remission in Multiple Myeloma, also known as MASTER, utilizes next generation sequencing technology to detect minimal residual disease down to a level of one cancer cell in 100,000 \u2014 or 100- to 1,000-fold more sensitive than traditional methods to evaluate response.\nThis is one of the first trials in multiple myeloma to use minimal residual disease as primary endpoint and the very first one to modify therapy based on achievement of minimal residual disease eradication.\nPatients will be monitored for relapse at the molecular level, before disease becomes again symptomatic.\nMore than improving the results of the initial treatment, the MASTER study will treat patients for the necessary time to confirm elimination of minimal residual disease and then discontinue therapy.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Most readers of this release will get the impression that this trial is unique, when actually several groups are testing the same drug combination. The release highlights the researchers\u2019 plan to use \u201cnext generation sequencing technology to detect minimal residual disease\u201d (MRD) and to use those MRD results to guide treatment. There is much discussion of using MRD to monitor response to therapy but it is certainly not ready for widespread use.\nSome of the other similar trials also track minimal residual disease, though a quick review of trial descriptions on www.ClinicalTrials.gov does not make clear whether this trial is unique in using the MRD test results to guide treatment decisions or whether this feature is important.\nSimilar trials include:\nA Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma\nDaratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma\nSelinexor and Backbone Treatments of Multiple Myeloma Patients\nAggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant\n2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy", "answer": 0}, {"article": "Dr. Sonia Friedman is an associate professor of medicine at Harvard Medical School.\nWhether Xeljanz should be used as a first treatment is still not clear, said Dr. Arun Swaminath, director of the inflammatory bowel disease program at Lenox Hill Hospital in New York City.\n\"Only future studies will determine whether it can be used as initial therapy for ulcerative colitis and what patients it would help the most.\"\n\"Treatment with oral tofacitinib is potentially a new treatment option for patients with moderate to severe ulcerative colitis, pending review by the [U.S. Food and Drug Administration],\" Sandborn said.\nIn the first trial, nearly 19 percent of the patients taking Xeljanz experienced a remission of their condition in eight weeks.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that this would be one of the few \u201cpill-based\u201d biologic treatments for ulcerative colitis, and also that these results indicate a possible new option for people who haven\u2019t seen symptom improvement with other medications.", "answer": 1}, {"article": "For more information about our products and organization, visit http://www.\nWhile the EarWell system is not new, the report is the largest study of congenital ear malformations treated with this approach--including a standardized approach to treatment and assessment of the results.\nDr. Byrd comments, \"The EarWell system is effective in eliminating or reducing the need for surgery in all but the most severe congenital ear malformations.\"\nBut treatment must begin early--preferably within the first three weeks after birth, according to the study by ASPS Member Surgeon H. Steve Byrd, MD, and colleagues of Pediatric Plastic Surgery Institute, Dallas.\nThe researchers review their experience with nonsurgical correction of congenital ear malformations in 175 infants.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release notes that: \u201cWhile the EarWell system is not new, the report is the largest study of congenital ear malformations treated with this approach\u2013including a standardized approach to treatment and assessment of the results.\u201d That earns it a satisfactory rating here. However, the release would have been much stronger if it had offered some information as to how these study findings related to previous evaluations of the EarWell system. Are they consistent with previous results? And if they diverge from those results, how so?", "answer": 1}, {"article": "You know your cholesterol, your blood pressure ... your heart gene score?\nResearchers say a new way of analyzing genetic test data may one day help identify people at high risk of having a heart attack at a young age in time to help.\n\"This is the first time polygenic scores have really been shown to reach the level of precision where they can have an impact\" on patient health.\nBut specialists in heart disease and genetics who weren't involved with the research called the new findings exciting because of their scope.\nIf the approach pans out and doctors adopt it, a bad score wouldn't mean that you'd get a disease, just that your genetic makeup increases the chance \u2014 one more piece of information in deciding on care.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "A genetic test capable of gauging a person\u2019s risk of multiple diseases, based on a test looking for multiple genes, is clearly interesting enough to warrant a story, although the success of the test in actual practice with patients may be far less than the optimistic statements the story allows the researchers to make.", "answer": 1}, {"article": ".\nThe drug also proved to be highly selective, meaning it hit the intended targets inside the body and did not cause troubling side effects.\nThat is the same receptor in the brain targeted by the weight loss drug Fen-phen, which was popular in the 1990s.\nThe experimental drug stimulates the 5-HT2C serotonin receptor, which is located in the hypothalamus, an area of the brain associated with regulation of food intake and metabolism.\nBut one of the two components of that drug made by Wyeth, fenfluramine, also hit a second target in the heart, which was linked to heart valve problems.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story described that lorcasein targeted the 5HT-2c serotonin receptor but was specific to the brain receptor as opposed to fenfluramin which was less selective and was found to also target a serotonin receptor in the heart.", "answer": 1}, {"article": "Honey is not only cheap and readily available, it's also generally safer than cough medicine, which can have side effects or be administered in the wrong dose.\n\"(Honey) is a cheap and effective treatment,\" said Dr. Ian Paul, lead investigator for the study.\n\"I would be reluctant to routinely recommend to all parents that they give honey, because in some rare cases children can have reactions to honey.\"\nThe study comes at a time when parents are on the lookout for new ways to give sick children relief.\nOne local pediatrician said she wouldn't discourage parents from trying honey with their children, but more studies are needed to draw solid conclusions.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentions that using honey as a treatment is not a new idea.", "answer": 1}, {"article": "\u201cThat\u2019s what\u2019s good about this program.\nSurprisingly, the older the patient, the greater the likelihood that she would text back, seeking more information.\nThe feasibility study was designed to see if texting could relieve some of the anxiety that comes with the fatigue, hair loss and other body changes that can accompany anticancer drugs.\nOne of the patients texted the program 1,217 times.\nThe text messages were most effective at reducing distress at the 2- and 4-month marks, according to the data presented by chief author Kuang-Yi Wen, an assistant professor in the Cancer Prevention and Control program at Fox Chase.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story lacked context about the increasing use of text messaging for patients support, including during chemotherapy, and it didn\u2019t explain how this system works. Did clinicians answer patients\u2019 texts, or were the answers given by a computer? It\u2019s not clear.", "answer": 0}, {"article": "Side effects of male hormone therapy can include erectile dysfunction (impotence), loss of sex drive, hot flashes, growth of breast tissue, loss of muscle and bone mass, weight gain, nausea, liver problems, fatigue, memory problems and mood swings.\nHe noted that the radiation treatments in use today differ from those given in 1994 when the trial began.\nThese findings are good news for some men, since the effects of short term of hormone therapy are reversible, D'Amico said.\nSo, that brings into question how much, if any, hormone therapy is needed, he added.\nAnd while short term hormonal therapy is \"not very toxic, there are [still] some toxicities,\" Jones noted.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was clear that the treatments in the study, with some modification, are currently available.", "answer": 1}, {"article": "In fact, my life has changed completely thanks to this research.\"\nThe research is part of a growing body of evidence showing that people with Type 2 diabetes who successfully lose weight can reverse their condition because fat is removed from their pancreas, returning insulin production to normal.\nIn addition, the team found that even patients who have had Type 2 diabetes for up to 10 years can reverse their condition.\nThis will examine how successfully people can reverse their diabetes through weight loss simply under the care of their family doctor and nurse.\nA previous study led by Professor Taylor, published in 2011, showed that diabetes could be reversed by a very low calorie diet.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The study addresses novelty through this statement: \u201cThe research is part of a growing body of evidence showing that people with Type 2 diabetes who successfully lose weight can reverse their condition because fat is removed from their pancreas, returning insulin production to normal.\u201d We think that\u2019s not quite appropriate positioning of the results. While it\u2019s true that there is considerable evidence from studies of weight loss surgery that diabetes values can be normalized with significant weight loss, this release is also suggesting that it has proven that all diabetes patients can reverse the disease through diet alterations, and that the benefits are due to a reduction in fat in the pancreas. These claims go too far based on the small study size and a demonstrated 40 percent success rate.", "answer": 0}, {"article": "Unlike the more common obstructive sleep apnea, in which the airway partially collapses and causes pauses in breathing, central sleep apnea (CSA) occurs when the brain fails to control breathing during sleep.\nAbout a third of patients in the treatment group reported therapy-related discomfort that was resolved with some reprogramming of the device.\nThe study was funded by Respicardia.\nAbraham, along with lead author Dr. Maria Rosa Costanzo at Advocate Heart Institute in Naperville, IL, led the study at 31 hospitals in the United States, Germany and Poland.\nBetween six and 12 months of follow-up, all patients received the neurostimulation treatment.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does not make any claim of novelty, and that\u2019s unfortunate. The published study did note that the trial was the first of its kind, to the best of knowledge of the researchers. But readers who don\u2019t go beyond the release won\u2019t be privy to this.", "answer": 0}, {"article": "It will also help remove the uncertainty surrounding which sub type of the disease an individual has and therefore be a catalyst for better outcomes for all people with MS.\"\n\nMultiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS).\nPublished today in Scientific Reports, the discovery identifies tiny 'dysregulated' micro-RNA molecules that correctly diagnose MS and discriminate between patients at different disease stages - all in a simple blood test.\nCurrently, there is no definitive test for MS.\nThe research team assessed the utility of microRNAs (miRNA) in serum (blood) exosomes as biomarkers of MS disease.\nA breakthrough study led by the University of Sydney's Brain and Mind Centre and Royal Prince Alfred Hospital has revealed unique molecules in the blood of people with Multiple Sclerosis (MS) that could become definitive diagnostic biomarkers of the world's most common neurologic disability in young adults.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The text repeatedly notes that this blood test could become the first definitive diagnostic test for MS.", "answer": 1}, {"article": "Barley reduced both low-density lipoprotein, or LDL, and non-high-density lipoprotein, or non-HDL, by seven per cent.\nThe research review, published today in The European Journal of Clinical Nutrition, included 14 studies on clinical trials conducted in seven countries, including Canada.\nDespite its benefits Dr. Vuksan said barley is not as well-established as some other health-recommended foods -- such as oats.\nIt is the first study to look at the effects of barley and barley products on both LDL and non-HDL cholesterol in addition to apolipoprotein B, or apoB, a lipoprotein that carries bad cholesterol through the blood.\n\"After looking at the evidence, we can also say that barley is comparably effective as oats in reducing overall risk of cardiovascular disease\" said Dr. Vuksan.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "We don\u2019t think the release established the novelty of the research in the manner it\u2019s claimed:\n\u201cIt is the first study to look at the effects of barley and barley products on both LDL and non-HDL cholesterol in addition to apolipoprotein B, or apoB, a lipoprotein that carries bad cholesterol through the blood.\u201d\nHow could it be the \u201cfirst study\u201d when it is looking at a group of studies? \u00a0Is it the first meta-analysis to examine this question? If so, that should be mentioned.", "answer": 0}, {"article": "The first figure is systolic pressure, generated when the heart is pumping, and the second figure is diastolic pressure, created when the heart is relaxing and filling with blood.\nAs for the next step in confirming the relationship between beetroot juice and blood pressure, she says this was a small trial.\nThe trial was double-blind, which means neither the administering clinicians nor the patients knew whether the beetroot juice they were given was the placebo or the active supplement.\nThey conducted a placebo-controlled trial with dozens of participants.\nThis is the first study that shows evidence of dietary nitrate supplementation's long-lasting benefit in a group of patients with high blood pressure.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that the new study builds on previous research by this team, and a quick search confirms that these researchers were among the first to investigate the blood pressure effects of beet juice.", "answer": 1}, {"article": "\u2022 Measure baseline omega-3 intake or status of study participants to determine the extent to which it confounds results.\n\"The 6 percent reduced risk among RCTs, coupled with an 18 percent risk reduction in prospective cohort studies -- which tend to include more real-life dietary scenarios over longer periods -- tell a compelling story about the importance of EPA and DHA omega-3s for cardiovascular health.\"\n\"There are important public health implications related to reducing the risk of coronary heart disease, and therefore we are encouraged by the results of this comprehensive analysis,\" said Dr. Harry Rice, Vice President of Regulatory and Scientific Affairs for the Global Organization for EPA and DHA Omega-3s (GOED), which funded the study.\n\"It's also important that the observed risk reductions were even stronger in patient populations with elevated triglycerides and LDL cholesterol levels, two risk factors that affect more than one quarter of the American population.\"\nStudy authors did point out that further clinical trials looking specifically at CHD outcomes may continue to provide a better understanding of the promising beneficial relationship between EPA/DHA and CHD risk.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "There are a ton (to use a technical term) of studies on omega-3 fatty acids and heart disease, including lots (and lots) of meta-analyses (like this one or this one, for example). What sets this meta-analysis apart? The release doesn\u2019t tell us.\nAs noted above under the Why This Matters section, there\u2019s considerable evidence and recent consensus that fish oil doesn\u2019t have much if any effect on cardiovascular disease.", "answer": 0}, {"article": "Infants exposed to partial treatment in the womb healthier than those not exposed.\nThe new study, supported by NIH\u2019s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), provides strong evidence that even a partial course can have some benefit.\nAdditional funding for the study was provided by NIH\u2019s National Center for Advancing Translational Sciences.\nThe study followed the infants from birth to 18 to 22 months of age and measured survival and brain and nervous system outcomes.\nInfants in the partial treatment group fared better than untreated infants.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "As implied by the news release, the main objective of the research was to look at the varying levels of treatment \u2014 in this case, no, partial and complete antenatal courses. Previously, physicians may have opted to forgo treatment when premature delivery is on the horizon, since an entire treatment course takes at least 48 hours. But according to the release, the new study gives \u201cstrong evidence\u201d that even a partial course can provide some benefit.\nThe release might better have characterized the study as yielding minimally statistically significant results rather than \u201cstrong evidence.\u201d\nBut overall, the news release merits a Satisfactory rating for novelty.", "answer": 1}, {"article": "The drug is Johnson & Johnson's abiraterone acetate.\nAnd while the average patient survived only four months longer than those on standard chemotherapy -- 14.8 months vs. 10.9 months -- some patients did much better.\nThe treatment gave patients with metastatic, castration-resistant prostate cancer only an extra four months of life.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\nDe Bono reported the study findings in at this week's meeting of the European Society for Medical Oncology in Milan, Italy.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story didn\u2019t provide any meaningful context about possible novelty of this approach.\u00a0 Again, let\u2019s turn to the competing Wall Street Journal story for comparison.\u00a0 It reported:\u00a0\"Androgen hormones, particularly testosterone, fuel prostate tumors. Conventional hormone therapy blocks androgens produced by the testes. Abiraterone appears to target androgens also produced elsewhere, even by the tumors themselves, said Dr. de Bono, who presented the study in Milan.\"\u00a0 This story only told us that \"It appears that abiraterone is able to shut down androgen production not only in the testes, but also from the adrenal gland and from within prostate tumors themselves.\"\u00a0 But that statement stands in isolation without any comparison to existing hormonal approaches. ", "answer": 0}, {"article": "Nov. 22, 2010 -- Exercising to piano music may help improve balance and prevent falls among the elderly.\n\nA new study shows older men and women who participated in a piano-music-based exercise program were less likely to suffer a fall than those who didn't. Those who exercised to piano music also showed improvements in balance and the manner or style of walking.\n\n\u201cEach year, one-third of the population 65 years and older experiences at least one fall, and half of those fall repeatedly,\u201d write researcher Andrea Trombetti, MD, of University Hospitals and Faculty of Medicine of Geneva, Switzerland, and colleagues in the Archives of Internal Medicine. \u201cExercise can counteract key risk factors for falls, such as poor balance, and consequently reduce risk of falling in elderly community-dwelling individuals.\u201d\n\nResearchers say a large proportion of falls in elderly people occur while walking, so improving gait and balance can have a major impact on fall prevention.", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\nThe story does not include any claims of novelty of this approach.\n\u00a0\nAnother New York Times article did call attention to this form of exercise with the headline: \u201cDalcroze Eurhythmics Have Come to New York.\u201d The article was published on January 25, 1914. There is indeed nothing new about the method of exercise.\n\u00a0\nReference:\nhttp://query.nytimes.com/mem/archive-free/pdf?res=F20E12FF355D13738DDDAC0A94D9405B848DF1D3\n", "answer": 2}, {"article": "They include people like Danielle Denlein, who, to her total shock, developed a serious heart problem.On October 20, 2008, at 1:50 p.m., Ms. Denlein was driving to a drug store to buy formula for her 5-day-old baby girl.\nIf successful, the smart device could have a big effect.\nOne solution, being tested by St. Jude Medical, a medical device company in St. Paul, is to let patients deal with important data.\nThose with the nontransmitting device were seen in their doctor\u2019s offices every few months, the standard of care.\nDr. Stevenson likened such information to the game of \u201cJeopardy!\u201d \u2014 doctors are given answers in search of a question.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The story wove together information from devices that available \u2013 through those used in clinical trials and those under development.", "answer": 1}, {"article": "The F.D.A.\nThe review for Medicare said there was insufficient evidence to judge whether Provenge would work if used off-label.\nThere is only \u201cmoderate\u2019\u2019 evidence that the newly approved prostate cancer drug Provenge helps patients, according to an analysis done for Medicare that was made public on Wednesday.\nThe analysis is part of a controversial review by the Centers for Medicare and Medicaid Services to determine whether to pay for Provenge, which costs $93,000 per patient and extended lives by about four months in clinical trials.\n\u201cHistorically, moderate means that CMS will reimburse the product for its on-label indication,\u2019\u2019 she wrote.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThe story reports that Provenge is the first approved treatment that is designed to try to stimulate a patient\u2019s immune system to attack tumors.", "answer": 1}, {"article": "The retina is the light-sensing nerve tissue at the back of the eye.\n\u201cThough additional pre-clinical data is needed, our institute is close to a time when we can offer adult stem cells as a promising source for personalized therapies for this and other human diseases.\u201d\n\nNext steps include testing the efficacy and safety of the stem cell injection in preclinical animal studies to provide information for applying for an investigational new drug.\n\u201cThese induced neural progenitor stem cells are a novel source of adult-derived cells which should have powerful effects on slowing down vision loss associated with macular degeneration,\u201d said Clive Svendsen, PhD, director of the Board of Governors Regenerative Medicine Institute and contributing author to the study.\n\u201cThis is the first study to show preservation of vision after a single injection of adult-derived human cells into a rat model with age-related macular degeneration,\u201d said Shaomei Wang, MD, PhD, lead author of the study published in the journal STEM CELLS and a research scientist in the Eye Program at the Cedars-Sinai Board of Governors Regenerative Medicine Institute.\nThis work was supported by the Simon and Beathrice Apple Stem Cell Fund for Eye Research, the David and Janet Polak Foundation Stem Cell Core Laboratory; National Institutes of Health (R01 EY020488), Department of Defense (W81XWH-12-1-0617), Foundation Fighting Blindness and the Knights Templar Eye Foundation Inc.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "We will give the news release the benefit of the doubt on this criterion. \u00a0But here\u2019s why it\u2019s a coin toss.\nThe release states:\u00a0\u201cThis is the first study to show preservation of vision after a single injection of adult-derived human cells into a rat model with age-related macular degeneration.\u201d\nThat may be. \u00a0There\u00a0are some ways in which these particular stem cells are novel. \u00a0But other stem cell approaches\u00a0have been developed and in some cases are in in early phase human\u00a0trials or animal tests.\nHowever, since we have already dinged this release in the \u201cAlternatives\u201d criterion above for failing to give that context, we\u2019ll give it the benefit of the doubt here.", "answer": 1}, {"article": "Only 30-50 people with type 1 diabetes in the UK currently receive an islet transplant each year, owing to a lack of donors and the difficulty of extracting islets from pancreatic tissue.\nThe pre-clinical results have encouraged CGT and Aberdeen University to create a spin-out company, called Islexa.\nInsulin shots could become a thing of the past for type 1 diabetes patients thanks to a technology being developed by Cell and Gene Therapy Catapult, a London-based not-for-profit organisation, and Aberdeen University.\nGrowing islets will \u201csignificantly increase the number of patients who can receive the treatment,\u201d Keith Thompson, CGT\u2019s chief executive, told the World Stem Cells and Regenerative Medicine congress in London on Wednesday.\nIf clinical trials are successful, the technology means tens of thousands more people could live without the need for frequent insulin injections, although it will take a few years until the treatment is available.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article makes it clear that the novelty would be how many more patients could, in theory, receive the treatment if this idea works once in clinical trials.", "answer": 1}, {"article": "Doctors diagnose Alzheimer\u2019s by excluding other causes of memory loss, such as stroke, tumors and heavy drinking.\nThe study is the latest to show that measuring disease-related proteins in spinal fluid is useful in diagnosing Alzheimer\u2019s disease.\nAnd they may also help identify early signs of the disease in healthy people, the team reported in the Archives of Neurology.\nBut biomarkers \u2014 proteins and imaging techniques \u2014 are helping to identify the disease much earlier.\nWhen they looked to see how accurate these signatures were at spotting the disease, they found 90 percent of those with Alzheimer\u2019s had the disease pattern in their spinal fluid.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story notes that this study is the latest to show that spinal fluid testing \u201cis useful in diagnosing Alzheimer\u2019s disease,\u201d thus indicating it is not the first such report.", "answer": 1}, {"article": "Dr. Steve Hicks, senior author of the study and an assistant professor of pediatrics at Penn State College of Medicine, said the \"five microRNAs in saliva could predict with approximately 85% accuracy which concussed children would have symptoms one month later.\nDr. Jeffrey Kutcher, a neurologist and National Director of The Sports Neurology Clinic at The CORE Institute, said that \"work like this is important because it does provide potential for tests that can be helpful in the clinical setting.\"\n(CNN) A saliva test may someday be able to diagnose a concussion and predict how long symptoms last, according to a study published Monday in the JAMA Pediatrics.\n'Way too early to know'\n\nHowever, the editorial authors, Dr. William P. Meehan III of Micheli Center for Sports Injury Prevention at Boston Children's Hospital in Massachusetts and Dr. Rebekah Mannix of Brain Injury Center at Boston Children's Hospital, noted that \"the relatively small sample size in this study requires larger-scale studies to determine the reliability\" of the results.\nStill, \"the findings are promising, representing potential biomarkers for the diagnosis, recovery, and prognostic assessment of a sport-related concussion.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "As mentioned earlier, the story quotes the JAMA Pediatrics editorial that accompanied the study as saying that the saliva test \u201crepresents an advance in the science of sport-related concussions.\u201d Thus, the test does appear to be a novel approach.", "answer": 1}, {"article": "During transcranial magnetic stimulation (TMS), a doctor places a large magnetic coil against the patient\u2019s scalp, which creates electric currents to stimulate nerve cells.\nThe overactive brain circuits also improved among people who got the TMS treatment, the study showed.\nThis is often not enough to make a meaningful improvement.\nThere were no improvements seen in test scores of those who got the other treatment.\nTen out of 20 people who faced this problem following a stroke received the magnet therapy daily for two weeks.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story quotes an expert who calls TMS \u201ca very novel treatment\u201d for stroke, which is accurate.\u00a0However, the story could have given more details about TMS\u2019s more established use as\u00a0a treatment for depression. The story alludes to this use, but doesn\u2019t convey that depression is what TMS was originally designed to treat and where it is most frequently employed.", "answer": 1}, {"article": "In Japan, \u201cfood and health care companies have found cosmetic applications for their ingredients, so they are creating skin care brands.\u201d\n\nFor example, Frutarom, a flavor-ingredient house based in Israel, makes Alguard, a purified polysaccharide shield from a red microalgae that it says protects skin from daily assaults and reduces roughness as well as the look of fine lines.\nThere are more than 100 algae-derived ingredients used in cosmetics worldwide, Mrs. Lewis said.\nBut Dr. McDaniel, who does research into using plant-derived products to lengthen the life of cells, says he thinks the comparative data must be viewed with caution because the studies that yielded it are \u201cchallenging to do accurately, hard to interpret and not necessarily predictive of final products.\u201d\n\nSoon, consumers will judge whether Algenist products are a breakthrough.\nDr. Dana Sachs, an associate professor of dermatology at the University of Michigan, Ann Arbor, wrote in an e-mail after looking at Algenist\u2019s dossier that \u201cthe claims on cell regeneration and elastin synthesis are based on in vitro models, which is hard to extrapolate to in vivo, and again no statistical significance is presented, so this is a weak claim.\u201d\n\nDr. Day, who has a doctorate in biochemistry, said that statistical significance was found but not included in press materials.\nThe patent-pending alguronic acid in Algenist is a \u201csingle, purified, highly bioactive compound,\u201d said Tony Day, the vice president for research and development at Solazyme, and therefore delivers \u201cmuch higher activity to the skin\u201d than products using only a microalgae extract.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does a good job describing why the company selling this product is excited about its prospects, but it never establishes what sort of edge, if any, this product would have on the thousands of other \u201canti-aging\u201d products being sold. There are hundreds of anti-aging products containing a product derived from seaweed. The suggestion that this one is somehow unique remains to be proven", "answer": 0}, {"article": "The American Orthopaedic Society for Sports Medicine (AOSSM) is the premier global, sports medicine organization representing the interests of orthopaedic surgeons and other professionals who provide comprehensive health services for the care of athletes and active people of all ages and levels.\n\"This type of osteochondral allograft transplantation has traditionally been used in younger active patients with cartilage disorders.\nAOSSM is also a founding partner of the STOP Sports Injuries campaign to prevent overuse and traumatic injuries in kids.\n\"Our findings note that patients older than 40 may benefit from using a fresh osteochondral allograft transplantation to treat focal cartilage defects, a common cause of knee pain in adults,\" said lead author, Dennis Crawford, MD, PhD from the Oregon Health and Science University in Portland, Oregon.\nGreatest changes were seen in the ability of patients to perform Sports and with improvement in healthful daily activity.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "There are dozens, if not hundreds, of journal articles out there regarding the use of osteochondral allograft transplantation to address knee problems. What sets this one apart? Presumably it is the first to directly compare outcomes between older and younger adults, but the release doesn\u2019t explicitly tell readers that.", "answer": 0}, {"article": "Newswise \u2014 RESEARCH TRIANGLE PARK, NC\u2014 Major depressive disorder affects more than 32 million Americans, and their first stop for treatment is often their primary care provider.\nThe authors focused specifically on comparing second generation antidepressants, such as Wellbutrin, Lexapro and Prozac with cognitive behavioral therapy, which includes several in-person or phone sessions with a therapist to examine how actions and thoughts can impact depression.\nAfter conducting a full review of the scientific literature available, the researchers examined 11 randomized controlled trials with 1,511 patients that compared a second generation antidepressant with cognitive behavioral therapy.\nThe research from the RTI International-University of Chapel Hill Evidence-based Practice Center was published today in the British Medical Journal.\n\"Major depressive disorder is a disabling and prevalent form of depression, experienced by more than 16 percent of U.S. adults during their lifetime,\" said Arlene Bierman, M.D., Director, Center for Evidence and Practice Improvement, at the Agency for Healthcare Research and Quality, which funded the study.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This meta-analysis research on CBT and antidepressants has been around the block a few times. A similar study involving 16 studies and 1700 patients and with a similar conclusion was published in JAMA Psychiatry in September 2015. Prior to being published in the BMJ, this research was presented at a 2014 neurology conference.", "answer": 0}, {"article": "Bleier said the device, which consists of a lead wire and a neurostimulator the size of a stopwatch, is implanted on top of a buttock muscle. Patients don't feel it when they sit down and you can't see its imprint under a tight pair of pants. Patients can try the stimulation for two weeks with the pacemaker outside the body before deciding whether to have it implanted, an outpatient procedure. Medicare pays about $21,500 for the device and treatment.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Except for the discussion of the pacemaker InterStim, the story didn\u2019t include any overt claims of novelty.\u00a0 And on InterStim it explained that this is a device originally approved for urinary incontinence and that it uses the same technology as a heart pacemaker.", "answer": 1}, {"article": "High blood pressure increases the risk for heart attack, stroke and kidney problems.\n\"Based on our findings, we conclude that this new method of using blood pressure-lowering drugs was more effective and just as safe as current approaches,\" lead author Ruth Webster said in a news release from the American College of Cardiology.\nThe findings, she said, \"should prompt reconsideration of recommendations around the use of combination therapy.\"\nThe rate of side effects was no greater among those who took the three-in-one pill than among the usual care group.\nAmong those who took the so-called \"triple pill\" for six months, 70 percent had achieved their blood pressure targets, compared with 55 percent of those who received their usual care.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t explain how this study fits into the body of research on combination blood pressure pills.\nAccording to the news release, lead researcher Ruth Webster, MBBS, of the George Institute for Global Health at the University of New South Wales, described the study as \u201cthe first large trial designed to test the theory that starting treatment with low doses and three drugs could achieve better blood pressure control compared with usual care and that combining these drugs in a single pill would make it easier both for doctors to prescribe treatment and for patients to adhere to it.\u201d", "answer": 0}, {"article": "Chinese herbal medicine increased IELT by about two minutes, Ayurvedic herbal medicine increased IELT by nearly a minute and topical cream increased IELT by more than eight minutes.\nBias was unclear in most of the studies, and only five used stopwatches to measure IELT, which is the \u201cgold standard\u201d for premature ejaculation studies, Patrick said.\nWhen they were reported, the adverse effects were generally mild, the study team writes.\nThe improvements were small, and the studies were of varying quality, but preliminary evidence suggests that acupuncture, Chinese herbal medicine, Ayurvedic herbal medicine and a Korean topical cream may all have desirable effects, researchers conclude in the journal Sexual Medicine.\n\u201cTo our knowledge, this is the first systematic review to assess complementary and alternative medicine for premature ejaculation.\u201d\n\nAccording to the International Society for Sexual Medicine, premature ejaculation can be a lifelong problem, and this primary form of the problem is usually defined as ejaculation happening within one minute of initiating vaginal intercourse every time a man has ever had sex.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The study establishes its novelty right up front, saying it is the first systematic review of the alternatives to treat premature ejaculation. Based on a literature search we conducted, this appears to be accurate.", "answer": 1}, {"article": ".\nThe new study, published in The European Journal of Internal Medicine, found cannabis therapy is safe and efficacious for elderly patients who are seeking to address cancer symptoms, Parkinson's disease, post-traumatic stress disorder, ulcerative colitis, Crohn's disease, multiple sclerosis, and other medical issues.\nWhile the researchers state their findings to date indicate cannabis may decrease dependence on prescription medicines, including opioids, more evidence-based data from this special, aging population is imperative.\nMore than 70 percent of patients surveyed reported moderate to significant improvement in their condition.\n\"After monitoring patients 65 and older for six months, we found medical cannabis treatment significantly relieves pain and improves quality of life for seniors with minimal side effects reported.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "There have been several other studies looking at the safety and efficacy of using medical cannabis in the elderly. A 2014 review of them concluded:\n\u201cAdequately powered trials are needed to assess the efficacy and safety of cannabinoids in older subjects, as the potential symptomatic benefit is especially attractive in this age group.\u201d\nThese other studies are not mentioned in the news release.", "answer": 0}, {"article": "Jason Dragoo\u2019s Stanford University research team gets 100 to 200 inquiries every day from people interested in joining its clinical trial studying the use of stem cells to treat knee injuries.\n\nThe interest highlights a growing demand for the use of stem cells derived from a person\u2019s own bone marrow or fat to treat orthopedic injuries. Osteoarthritis, a degenerative joint disease where the protective tissue or cartilage around a joint wears down, is a particular focus of inquiry.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear this is an emerging technology that is currently being tested to see how it compares with existing approaches.", "answer": 1}, {"article": "We can't find the page you're looking for. Try one of these options.\n\nAre you sure this is the right web address? Let us know.", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The novelty of the medical device is established in the first sentence. The news release reports DigniCap is the first cooling cap cleared for marketing in the United States to reduce hair loss in female breast cancer patients undergoing chemotherapy.", "answer": 1}, {"article": "Essential fatty acids are substances that are not produced by the human body and are only available from diet.\nThe study, published Monday in the journal Reproductive Health, found that taking capsules containing about 1 gram of a blend of three essential fatty acids produced a significant reduction in PMS symptoms.\nThe study, authored by researchers from the Federal University of Pernambuco, is not the first to address the possible link between PMS and essential fatty acids, substances that play a complicated role in a woman's reproductive system.\nAccording to the study, the 120 women who participated reported few side effects, and most of those were mild and may have been due to sensitivity to mineral oil, the placebo taken by some of the participants.\nAccording to the study, women who took the supplements for six months saw a bigger benefit than those who took them for three months.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The idea of using supplements for PMS is not new, and the authors mention past research on the same topic.", "answer": 1}, {"article": "As we cut calories and lose weight, our resting metabolic rate eventually slows and our bodies become less efficient at shedding mass in a process known as adaptive thermogenesis.\nThe dieters ate enough calories to maintain their weight during the off period.\nHowever, it\u2019s important not to think of them as cheat days.\nWhile frustrating, it\u2019s one of our natural survival mechanisms to prevent potential starvation.\nThe experimental group stuck to the eating plan for two weeks, before ditching the diet for two weeks.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article explains how this diet differs from some others.", "answer": 1}, {"article": "Oct. 17, 2010 -- Women aged 65 and older are advised to undergo bone mineral density (BMD) screening every two years, but those with normal results at age 67 may be able to wait 10 years before their next screening test, a new study suggests.\nTheir findings are based on the women's T-score, which is a measure of bone density.\nResearchers analyzed bone mineral density data from 5,035 women aged 67 or older who had their BMD tested at least twice during the 15-year study period.\n\"Our study found it would take about 16 years for 10 percent of women in the highest bone density ranges to develop osteoporosis.\nThe new findings are slated to be presented at the annual meeting of the American Society for Bone Mineral Research in Toronto.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty here is not bone density screening, but less frequent use of this widely used test. Sadly, research that looks at screening intervals is a novelty.\u00a0But neither story establishes that novelty. The study appears to be quite significant given the size of the cohort and the time period of the study.", "answer": 0}, {"article": "\"So, yes, one of the limitations of this kind of study is always the question of its generalizability to other populations,\" he cautioned.\nRamsden acknowledged that the Sydney study had been narrowly focused on a specific group of people: middle-aged men with a history of heart disease, who were asked to consume linoleic acid in quantities far exceeding both AHA guidelines and the dietary habits of most Americans.\nWEDNESDAY, Feb. 6, 2013 (HealthDay News) -- Enduring dietary wisdom -- that polyunsaturated vegetable fats are better for your heart than saturated animal fats -- may be turned on its head by a fresh analysis of a nearly 50-year-old study.\n\"Because there's very robust evidence showing the cardiovascular benefit of linoleic acid.\nBut he also suggested that his team's rigorous look back offered valuable insights into how nutritional science has evolved.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It has long been known that the\u00a0subjects in the linoleic acid/safflower oil group of this study had higher all-cause mortality. What was unclear is if they had higher cardiovascular mortality.\u00a0The results are not quite as novel as the story suggests.\u00a0 Nonethless, we\u2019ll give the story the benefit of the doubt on capturing the overall gist of the novelty of the study adequately.", "answer": 1}, {"article": "Strawberries have the potential to prevent esophageal cancer, according to a preliminary study released Wednesday.\n\nResearchers, led by Ohio State University, were able to show that freeze-dried strawberries slowed the growth of dysplastic, or precancerous, lesions in about 30 people who consumed the fruit for six months.", "question": "Does the story establish the true novelty of the approach?", "explanation": "At least the story noted that \u201cPrevious work showed that freeze-dried strawberries were able to significantly inhibit tumor development in rats.\u201d So there was no claim that this was first-in-its-field research.", "answer": 1}, {"article": "Aggression scores declined to 3.8 from 7.1 in the dextromethorphan-quinidine group and to 5.3 from 7.0 in those who took a placebo.\nNow researchers report that a combination drug already in use for treating certain neurological problems may be a better remedy.\nThere are no currently approved treatments for agitation, and we\u2019re very enthusiastic about this finding.\u201d\n\nCorrection: October 8, 2015 \n\nA report in the In Brief column on Sept. 29 about a combination drug that could ease the agitation of Alzheimer\u2019s disease described incorrectly a disorder treated with the combination drug, dextromethorphan and quinidine.\n\u201cFifty-five percent of the people who were on drugs had a 50 percent reduction in their agitation,\u201d said the lead author, Dr. Jeffrey L. Cummings, director of the Cleveland Clinic Lou Ruvo Center for Brain Health.\nResearchers then rated them using a well-validated scale that measures aggression and agitation.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "To our knowledge, this is the first study to examine the efficacy of dextromethorphan-quinidine in patients with Alzheimer\u2019s disease.\u00a0The story notes that \u201cAgitation and aggression are common in Alzheimer\u2019s patients, and there is no known safe and effective treatment.\u201d We think that\u2019s enough to establish novelty.", "answer": 1}, {"article": "\"In many of those cases we decide, 'OK, this lesion is too small to be treated with a filling.'\nThe treatment, called Icon, is one of several new cavity treatments that avoid drilling.\nAvoiding the drill has the advantage of preserving and extending the life of the natural tooth.\nThe new treatment uses a coating of mild acid that is applied to the decay to open up a route to the pores and clear out decayed enamel.\nTo Drill Or Not To Drill\n\nPhark says that when decay is caught very early or very late, dentists have a clear course of action: Early problems can often be reversed with better brushing, fluoride or calcium-containing toothpastes -- and late-stage cavities need to be filled.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\n\n \nThis story fails spectacularly on this criterion. The featured product is called \u201cone of several new cavity treatments that avoid drilling.\u201d But in its application for approval to the FDA, the manufacturer says the product is basically the same as other sealants that have been available for more than a decade:\n\u201cThe Infiltration Kit materials are substantially equivalent to several currently marketed dental restorative materials including the following:Infiltrant:3M CliNPRo Sealant K992326 (3M Company USA)Admira Seal K021842 (VOCO, GmbH)Grandio Seal K062344 (VOCO, GmbH)\nReferences:FDA 510k summary, March 26, 2010http://www.accessdata.fda.gov/cdrh_docs/pdf10/K100062.pdf\nFDA 510(k) Summary, Sep. 18, 2008http://www.accessdata.fda.gov/cdrh_docs/pdf8/K081493.pdf", "answer": 0}, {"article": "He explained: \"When teixobactin was discovered it was ground breaking in itself as a new antibiotic which kills bacteria without detectable resistance including superbugs such as MRSA.\nThe Lincoln team has successfully synthesized new simplified versions of teixobactin which harness the same powerful antibiotic effects in a way that could be produced on a commercial scale.\nThe work builds on the success of the team's pioneering research to tackle antimicrobial resistance over the past 18 months.\nWe have been investigating a way to simplify the design while retaining the high potency against resistant bacteria such as MRSA.\nThe breakthrough by researchers at the University of Lincoln, UK, marks another important step to realising the potential of teixobactin in aiding the global fight against antibiotic-resistant pathogens.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release states that the researchers created versions of the teixobactin antibiotic that can be produced far more quickly and efficiently than the natural form. It also notes that this announcement builds on research done over the past 18 months.", "answer": 1}, {"article": "ASTHMA According to conventional wisdom, asthma and other allergic diseases like hay fever are made worse by dirty environments. Recent evidence has suggested, however, that children exposed to dirt and germs early in life may have a lower risk of developing asthma and other allergies. Studies have found that the children of farmers -- who presumably are exposed to a ... (Full article: 838 words)", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u2019s fairly clear from the story that the use of medication as a means of reducing the risk of developing hypertension in patients with pre-hypertension but without other conditions is new. ", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061008/16healthwatch.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "This story reported on the results of a study that found that bone mineral density in women\u2019s\u2019 hips had an inverse relation to self reported levels of cola consumption.", "answer": 1}, {"article": "Dec. 2, 2011 (Chicago) -- An experimental approach in which penile nerve tissue is frozen to knock out overactive nerves helped men with premature ejaculation last three times longer.\nBut other experts tell WebMD that questions about the long-term consequences remain.\nA time to ejaculation of more than two minutes is normal, he tells WebMD.\nThe findings were presented here at the annual meeting of the Radiological Society of North America.\nIts supporters say the technique, or a similar one involving heat therapy, could someday become a standard treatment for the condition.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t exaggerate the novelty of the procedure.", "answer": 1}, {"article": "Study author Dweik added that the test is \"theoretically cheap.\nThis study is really a proof of concept.\nSome of those compounds had been pegged as potential telltale signs of heart failure.\nBut of course we're still early in the process of exploring its potential.\nSo there may be potentially less of a role for a breath test in that kind of setting.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This sort of breath test would be a new addition to heart failure diagnosis, if it works.", "answer": 1}, {"article": "\"Our idea was to find a way to do a quick examination that would allow, during a boxing or American football match for example, to determine whether the athlete can return to the field or if his condition requires hospitalization.\nHis team has developed a rapid diagnostic test (POCT) called TBIcheck, inspired by the principle of pregnancy testing: by placing a single drop of blood on the well of a small 5cm plastic case, the patient knows within 10 minutes whether there is a risk of mild trauma, namely whether or not his H-FABP level is higher than 2.5 nanograms per millilitre of blood.\nToday, the injured patients have to go to the emergency rooms of hospitals equipped with a CT Scan, an expensive examination that sends X-rays to the brain to detect the presence or absence of brain trauma.\nYet 90% of these patients will be able to return home safely, as no trauma has been detected.\nThis discovery, described in PLOS ONE, will not only relieve emergency departments, free patients from often long waits, but also save on costly medical examinations.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "At least one other blood test to evaluate concussions has been given the green light to be marketed in the U.S., and that\u2019s not mentioned. HealthNewsReview.org reviewed a news release and a CNN story about that device.", "answer": 0}, {"article": "Michael Burk found walking increasingly painful last year. Crossing the street and tying his shoes became challenges, and colleagues noticed he was limping at work.\n\nOn a recent morning, Mr. Burk reported to the Hospital for Joint Diseases, part of NYU Langone Medical Center in New York City, for hip-replacement surgery. His surgeon had promised him a better quality of life, and said both the operation and recovery would be quick.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story should have been clearer about what is new here. The headline implies that the newness is driven by the increasing popularity of the anterior surgical approach: \u201cSame-Day Hip Replacement Hip replacement surgery is now an outpatient procedure due to an increasingly popular surgical technique; surgeons promise less pain and faster recovery.\u201d\nBut the surgical approach is not new at all, as the text of the story acknowledges\u2013it\u2019s been around forever and was old even when one of us (orthopedist James Rickert, one of four reviewers on this piece) was a resident in the 1980s. What is new is the same-day discharge, which in turn is driven by new and better pain medications and reimbursement schedules that yield greater profits the shorter the hospital stay. The story didn\u2019t zero in on this.", "answer": 0}, {"article": "An electromagnetic wave then agitates water molecules in the surrounding tumor tissue, producing friction and heat that eventually destroy the tumor.\nU.S. researchers say the technique certainly shows promise.\nThe findings were presented here at the annual meeting of the Radiological Society of North America.\nThe procedure, which costs about $2,000, takes about an hour, and the patient is typically kept overnight in the hospital for observation.\nIn a preliminary study, the technique, called microwave ablation, eliminated lung tumors in 19 of 28 patients.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "As with the \u201cavailability\u201d criterion, the novelty of the technique is a bit of a mystery, although the story does say that \u201cmicrowave ablation is being studied for the treatment of liver, kidney, and bone cancers.\u201d\u00a0 How long has it been studied or in use?\u00a0 We\u2019re not given a clue.", "answer": 0}, {"article": "Their average age was 69.\nThere needs to be a large head-to-head trial between Forteo and abaloparatide, she said, to really see which drug is better.\n\"Everybody is going to want to know if this is inferior or superior to Forteo,\" she said, adding that this is an early study.\nThere were no differences among the groups in other serious side effects, such as nausea and heart palpations, Miller said.\nAn editorial accompanying the study said which drug is selected may be less important than identifying and starting an approved treatment.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not make clear the novelty of abaloparatide, and seems to focus rather on the similarities between it and Forteo.", "answer": 0}, {"article": "An experimental Johnson & Johnson drug substantially reduced the severity of the inflammatory skin disorder psoriasis, according to a new study.\n\nJ&J is developing ustekinumab as part of a new category of drugs that targets proteins known as interleukins. In addition to psoriasis, J&J is studying the compound's potential to treat Crohn's disease, a gastrointestinal ailment.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of this class of \"self-injectable biologic\" drugs was discussed in the story. ", "answer": 1}, {"article": "She\u2019s healed, basically,\u201d she said.\nDiamond developed the vaccine and has been studying its effectiveness in clinical trials at COH since 2010.\nThe researchers tested this vaccine, known as p53MVA, in a 2013 clinical trial and found it to be safe in patients with advanced gastrointestinal cancers.\nHowever, patients whose T cells had pre-existing high levels of a protein named PD1 \u2014 a molecule that instructs immune cells to shut down \u2014 responded poorly to the anti-p53 vaccine.\nReferred to City of Hope by her physician at Davis, she began responding to the experimental treatment right away, Yuan said, her skin tumors disappearing and the latest biopsies showing no cancer.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release notes the p53 vaccine has been used in clinical trials since 2010. The release isn\u2019t claiming that the vaccine is brand new and has never been studied before. The\u00a0new information reported in the release is that one patient apparently responded favorably to the treatment, at least in the short-term.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070723/23healytip.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story included information that the observed association between LDL cholesterol level attained and cancer risk is something that has been previously reported.", "answer": 1}, {"article": "Compared with the 35 stroke patients who got clot-dissolving medicine alone, the 35 who got the two-pronged treatment were nearly twice as likely to regain some neurological function after three days. Imaging results revealed that for those who got both treatments, 100% of the brain tissue initially affected by a clot had blood flowing to it after 24 hours. Among the subjects who only got alteplase, the median level of restored blood flow was 37%.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story provides a good deal of background information and discusses how the new study results are different from previous experience. Readers are told that the procedure cannot be done by all hospitals, and only very specialized centers are capable of performing it. We would have appreciated a bit more information on why experts think the new results are so different from those of previous studies. In other words, why did these treatments succeed now when they\u2019ve failed to show benefit in the past?", "answer": 1}, {"article": "\"Here in the U.S., we do things differently,\" he said.\nEven though the ephedra-containing herbal is not readily available in the United States, the M-Y herbal formula is available in many countries besides China, including Korea, Japan, India and Germany, the study authors noted.\nCao and Wang, who specialize in infectious diseases and clinical microbiology, said the herbal recipe -- known as maxingshigan-yinqiaosan (M-Y) -- is easily accessible throughout China and much less expensive than Tamiflu (oseltamivir).\nHowever, finding the medicine in the United States is difficult, if not impossible, given that it contains the stimulant ephedra.\nBut the herbal formula is working on symptoms to help people become more comfortable.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that herbal remedies like the one tested in this study have been used for thousands of years in China.", "answer": 1}, {"article": "But high blood pressure also appears to increase a person's risk of developing Alzheimer's disease, which is associated with the accumulation of plaques and tangles in the brain.\nAnd he says other people with high blood pressure should follow his lead.\nKoroshetz is using all of these approaches.\nHe is responsible for the institute's public health campaign called Mind Your Risks.\nAt least two large studies have revealed an alarming trend among stroke patients, Koroshetz says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that the news \u201chook\u201d is new research to be presented at the Alzheimer\u2019s Association meeting. (Why not wait for that, to make this story meatier?)", "answer": 1}, {"article": "The page may no longer exist or may have moved to another web address. Try again to locate what you want by choosing a section from the navigation menu at left, viewing our Site Map or using the search box below.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article mentions that alternative therapies are not new and says that hypnosis \u201cis among the many non-drug treatments to which women turn for hot flash relief.\u201d", "answer": 1}, {"article": "Alcohol is known to activate some of the same receptors in the brain that opioids do, and studies find that by tempering the pleasure from alcohol, naltrexone can help people drink less.\nNaltrexone is certainly not a cure-all, researchers say.\nAnd it won't help everyone who has a drinking problem \u2014 especially if the disorder is severe.\nIt's now been about five months since he started taking the medication.\nHe says that when used alone the medicines are only modestly effective.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that this drug has been around a long time, and what\u2019s\u00a0novel here is a recent analysis showing that it is underutilized.", "answer": 1}, {"article": "According to a study published in the journal Birth, labor clears liquid from the infant's lungs, preparing the baby to breathe outside the womb.\nBut defining medical necessity is complicated.\nAnd some women are scheduling them early.\nBut the image that viewers may find most shocking is that of a baby being cut out of a woman's abdomen via Caesarean.\nDoctors such as Stark say we need a better sense of what goes on while the baby is still in utero.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Clearly C-sections are not new.", "answer": 1}, {"article": "Doctors in Seattle cured a late-stage cancer patient after tinkering with his body's defenses against infection, leading to cautious optimism about treating late-stage melanoma, a deadly skin cancer.\n\nThe surprising result, published in this week's issue of the New England Journal of Medicine, is the latest hopeful finding from the 30-year-old field of \"adoptive immunotherapy,\" which theorizes that the body can be taught to fight off its own cancers.", "question": "Does the story establish the true novelty of the approach?", "explanation": "\nThe story does a nice job of placing this story in its historical context, explaining that the new therapy comes out of the field of \"adoptive immunotherapy,\" which has evolved over the course of some 30 years.\n", "answer": 1}, {"article": "In those procedures, doctors either extract a small amount of the fluid that surrounds the fetus (amniocentesis) or they take a sample of the placenta (chorionic villus sampling).\nWhile it\u2019s available over the Internet, she said her team had only looked at hospital-based test performance.\n\u201cBut it should only be used by families that are at risk for sex-linked diseases.\u201d\n\nBianchi said she owns stock in Verinata Health, a company that is developing cell-free fetal DNA tests for Down syndrome, although that company had no role in the new study.\n\u201cIf parents are using it to determine gender and then terminate the pregnancy based on that, that could be a problem,\u201d she told Reuters Health.\n\u201cRemember, gender is not a disease.\u201d\n\nThe test looks for small pieces of the male sex chromosome in the mother\u2019s blood, which would mean she is carrying a baby boy.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The test is not novel. The story explained this was a \u201cfresh look at the medical evidence for the blood test.\u201d", "answer": 1}, {"article": "In traditional Chinese medicine, acupuncture involves inserting long, very thin needles just beneath the skin's surface at specific points on the body to control pain or stress.\nThe analysis was more rigorous than most research based on pooling previous studies' results, because the authors obtained original data from each study.\nThe new analysis was published online Monday in Archives of Internal Medicine.\nTheir study isn't proof, but it adds to evidence that acupuncture may benefit a range of conditions.\nThe new analysis examined 29 studies involving almost 18,000 adults.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story gives appropriate background on acupuncture research and how the new study differs from previous approaches.", "answer": 1}, {"article": "Irritable bowel syndrome can be highly debilitating, if not virtually paralyzing, and affect work, sleep and personal and family relationships.\nThat\u2019s the result of research by the University of Michigan Health System, presented at Digestive DiseaseWeek, that studied for the first time in the United States the result of following a carefully controlled diet to improve the symptoms and quality of life for those with irritable bowel syndrome.\n\u201cThis is the only methodically rigorous clinical trial to show that diet-based therapy can not only improve symptoms, but also quality of life in patients with IBS,\u201d says U-M assistant clinical professor and gastroenterologist Shanti Eswaran, M.D., who researches the role of diet and food in functional bowel diseases such as IBS.\nBecause of the many unknowns about the chemical causes and triggers of IBS, the list of \u201cbad\u201d foods is exhaustive and elusive, and help from a dietician is highly recommended.\nMeanwhile, we strongly recommend that IBS patients work with their physician and a registered dietitian to navigate the Low-FODMAP diet to take control of their IBS symptoms.\u201d\n\nEswaran received funding to conduct the research from the University of Michigan Nutritional and Obesity Center and Prometheus Diagnostics.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release states that the low FODMAP diet isn\u2019t new. But it also states that the study is the \u201cfirst of its kind,\u201d \u201cthe largest of its kind,\u201d and that this is the first time the FODMAP diet has been studied in the United States.", "answer": 1}, {"article": "States that permitted medical dispensaries -- regulated shops that people can visit to purchase cannabis products -- had 3.742 million fewer opioid prescriptions filled per year under Medicare Part D, while those that allowed only home cultivation had 1.792 million fewer opioid prescriptions per year.\n\"And for pain patients in particular, our work adds to the argument that cannabis can be effective.\"\nAll of these states include chronic pain -- either directly or indirectly -- in the list of approved medical conditions for marijuana use, according to Bradford.\n\"There is a great deal of movement in the Northeast, with New Hampshire and New Jersey being well-positioned to legalize adult use,\" Moore said.\n\"I don't think that's the only reason, but certainly, it was too easy at many points to get prescriptions for opioids.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explained that marijuana has been shown to be effective in treating chronic pain, and noted that more research is needed on its medical benefits.", "answer": 1}, {"article": "About the University of Maryland School of Medicine\n\nThe University of Maryland School of Medicine was chartered in 1807 and is the first public medical school in the United States and continues today as an innovative leader in accelerating innovation and discovery in medicine.\nProton therapy is just one of several new methods for treating cancer.\nWorking with colleagues at the Mayo Clinic in Rochester, Minnesota and the MD Anderson Cancer Center in Dallas, Texas, Michael Chuong, MD, an assistant professor of radiation oncology at the school, compared two kinds of X-ray radiation with proton therapy, an innovative, precise approach that targets tumors while minimizing harm to surrounding tissues.\nWhile most cancer patients are well served with today's state-of-the-art radiation therapy technology, up to 30 percent are expected to have a greater benefit from the new form of targeted proton beam therapy.\nThis technique can precisely direct radiation to the most difficult-to-reach tumors.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Proton therapy has garnered widespread attention for years because it is reported to cause fewer side effects than other treatments. This study was looking specifically at side effects of proton therapy\u2019s use when treating esophageal cancer, which may be a novel application for the technology. However, the story doesn\u2019t make that sufficiently clear. Is this the first time that researchers have analyzed the effects of proton beam therapy on esophageal cancer? Or is it adding to a body of research on this condition? The story could have earned a Satisfactory rating by clarifying that point.", "answer": 0}, {"article": "As many as 20 percent of American adults have some symptoms of irritable bowel syndrome, according to the National Institutes of Health.\nThe developer, Ironwood Pharmaceuticals, said the drug, linaclotide, met all the goals in the first late-stage trial testing it as a treatment for the type of irritable bowel syndrome accompanied by constipation.\nSome drugs that treat the pain, including opiates, can make the constipation worse, he said.\nAn experimental drug can reduce abdominal pain and increase bowel movements in people with irritable bowel syndrome, a condition that affects millions of Americans, the drug\u2019s developer said Monday.\nLaxatives can relieve the constipation but often do not help with the pain, said Dr. Chey, who is a consultant to Ironwood.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story could have mentioned the many other drugs that are in development for treatment of IBS, including one\u2013prucalopride\u2013which was recently approved in Europe. However, we don\u2019t think this story oversold the novelty of the new treatment.", "answer": 1}, {"article": "\u201cWe put a key onto the surface of the T-cells that fits into a lock that only the cancer cells have,\u201d said Dr. Michael Kalos, director of translational and correlative studies at the University of Pennsylvania\u2019s Perelman School of Medicine and an investigator on the study.\nThe treatment appears safe, but researchers said more study was needed.\nThe research group plans to treat four more patients with CLL before moving into a larger Phase II trial.\nTwo participants in the Phase I trial have been in remission for up to a year.\nThe results provide \u201ca tumor-attack roadmap for the treatment of other cancers,\u201d including those of the lung and ovaries as well as myeloma and melanoma, researchers said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Satisfactory job establishing the novelty \u2013 even in the first line of the story.", "answer": 1}, {"article": "A growing number of doctors who treat the estimated 6.4 million American children diagnosed with A.D.H.D.\nYet Dr. Bertin has recently changed the way he talks about medication, offering parents a powerful argument.\nOne possible reason, as the report noted, was that many children refuse to continue taking medication after a year or so, something most parentsof such children well know.\nDr. Swanson, a co-author of a landmark federally funded study, the Multimodal Treatment of Attention Deficit Hyperactivity Disorder, said that follow-up research found overall improvement but no greater long-term benefits after three years for children who were treated with medication compared to those who weren\u2019t.\nRecent research, he says, suggests the pills may \u201cnormalize\u201d the child\u2019s brain over time, rewiring neural connections so that a child would feel more focused and in control, long after the last pill was taken.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The key point of the story is that experts are applying relatively recent study results and theories about the effects of ADHD medications on the brains of children. While the drugs themselves have been in use for many years, the story presents evolving views about how to apply the results of recent studies to treatment decisions. As the story notes, recent research might encourage more parents \u201cto start their children on these medications early and continue them for longer.\u201d", "answer": 1}, {"article": "But the F.D.A.\nThe tests, though, were not necessarily specific for Alzheimer\u2019s and none had been studied to see if they accurately predicted plaque on autopsy.\nBut what is not known because no one could follow the development of plaque before a person died, was whether people with plaque and normal memories were developing Alzheimer\u2019s.\nAvid suggested that after the first 35 died, there should be enough data to know if the scans gave a true picture of the pathology.\nBrain scans that showed plaque could help with some fundamental questions \u2014 who has or is getting Alzheimer\u2019s, whether the disease ever stops or slows down on its own and even whether plaque is the main culprit causing brain cell death.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that \"There is no treatment yet to stop or slow the progress of Alzheimer\u2019s. But every major drug company has new experimental drugs it hopes will work, particularly if they are started early.\" And it goes on to say that, \"Other tests are being studied \u2014 ones that look for amyloid in cerebrospinal fluid that bathes the brain; MRI scans that look for shrinkage of the brain in areas needed for memory and reasoning; PET scans that look for uptake of glucose, a cellular fuel, to show areas where the brain was active and where it was not. The tests, though, were not necessarily specific for Alzheimer\u2019s and none had been studied to see if they accurately predicted plaque on autopsy.\"", "answer": 1}, {"article": "March 31, 2010 -- A widely prescribed drug used to shrink enlarged prostates appears to reduce the incidence of prostate cancer in men with an increased risk for the disease.\nWhile the studies suggest a role for Avodart and Proscar in the prevention of prostate cancer, experts tell WebMD that important questions remain about using the drugs for this purpose.\nStudy researcher Gerald L. Andriole, MD, says a significant proportion of men screened for prostate cancer fall into this clinically ambiguous category of having elevated PSAs and negative biopsies.\nBut none had evidence of cancer when biopsies were performed within six months of entering the trial.\nScheduled biopsies were performed two and four years after they entered the trial.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Clearly, Avodart is not a new drug, however, the idea that it could be used to prevent prostate cancer is relatively new.", "answer": 1}, {"article": "Among women receiving talazoparib, 55 percent had blood disorders, mostly anemia, compared with 38 percent of those receiving standard chemotherapy.\nThis targeted form of treatment takes advantage of a weakness in the BRCA gene to further cripple the cancer cell's ability to repair itself, grow and spread, said Weiss, who was not involved with the study.\nSimilar drugs have already been used to treat advanced, BRCA-mutated ovarian cancer, according to the agency.\nAs a result, more cancer cells are killed with fewer side effects, Weiss said.\nThe trial was funded by drug maker Pfizer, and the results were published Aug. 15 in the New England Journal of Medicine.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t articulate what\u2019s new about this finding \u2014 except the drug used. With another similar drug already on the market, what might this new drug offer? Is there an unmet need?", "answer": 0}, {"article": "In atopic dermatitis, the skin develops red, scaly and crusted bumps, which are extremely itchy,\u201d the FDA says.\nThe agency gave it both priority review and breakthrough therapy status, speeding it through the approval process.\nIn a nod to the sensitivity around drug prices, the company stressed that there is no single price for the drug.\n\u201cOf the adults with uncontrolled moderate to severe atopic dermatitis in the United States, it is estimated that 300,000 are most in need of new treatment options,\u201d Regeneron said.\nIt\u2019ll cost $37,000 a year but the drug\u2019s makers, Regeneron Pharmaceuticals and Sanofi, have stressed that\u2019s the wholesale price and make a point of saying there will be programs to help people pay for it.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story alludes to distinguishing features of the drug and notes that the FDA \u201cgave it both priority review and breakthrough therapy status, speeding it through the approval process.\u201d\nIt could have done a better job of explaining how many people are likely to benefit, other than the 300,000 the manufacturers describe as \u201cmost in need of treatment options.\u201d", "answer": 1}, {"article": "A surgically implanted electrical device that stimulates the sacral nerve can calm an overactive bladder, according to a company that sells it. Physicians say sacral neural stimulation works well for many patients, but a test period with an external device is recommended first.\n\nMillions of Americans suffer from \"urge incontinence,\" accidents caused by a strong, sudden need to get to the bathroom, or overly frequent urination, defined as eight or more times a day. Quality of life is affected, as sufferers must...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story accurately represents the novelty of the device.", "answer": 1}, {"article": "Sept. 26, 2017.\nThe research, published Sept. 26 in the Journal of the American Medical Association, reports results from the clinical trial known as GIFT (Genetics Informatics Trial of Warfarin to Prevent Deep Venous Thrombosis).\nUnlike prior studies, GIFT took into account genetic variants in three genes for 11 days of warfarin therapy.\nNo patient died during the trial.\nOne group received warfarin dosing based on standard factors such as age, height and weight; the second group was dosed based on these clinical factors plus genetic variants.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release describes how the genetic test used in the new study differs from previous similar studies.", "answer": 1}, {"article": "Their waistlines shrank by 1 to 2 inches.\nOur mouse studies using a similar fasting-mimicking diet indicate that these beneficial effects are caused by multi-system regeneration and rejuvenation in the body at the cellular and organ levels.\nThe researchers found that participants on the fasting-mimicking diet lost an average of about 6 pounds.\nIn effect, the diet reduced the study participants' risks for cancer, diabetes, heart disease and other age-related diseases, according to the findings published Feb. 15 in Science Translational Medicine.\nThe phase II trial, conducted by researchers at the USC Leonard Davis School of Gerontology, demonstrated a host of benefits from the regimen.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release states that this is the \u201cfirst randomized clinical trial with enough participants to demonstrate that the diet is feasible, effective and safe for humans.\u201d\nThe diet being tested is named by the researchers as a \u201cfast-mimicking diet\u201d or FMD.\nWhile this may be the first test of a \u201cfast-mimicking diet\u201d reliant on the ProLon diet kit, the concept of very low-calorie diets is not new and there are hundreds of clinical trials that have delved into reducing risk for cardiovascular disease via diet. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) discusses very low-calorie diets on its web page.", "answer": 0}, {"article": "\u201cBut it is definitely a breakthrough.\n\u201cThis is not a quick fix, and it doesn\u2019t mean people with peanut allergy will be able to eat peanuts whenever they want,\u201d Jay Lieberman, MD, vice chair of the ACAAI Food Allergy Committee and study co-author, said, according to EurekAlert.\nThe study\u2019s authors noted that patients would need to stay on the drug in order to receive protection against the allergy.\n\u201cWe\u2019re excited about the potential to help children and adolescents with peanut allergy protect themselves against accidentally eating a food with peanut in it,\u201d said allergist Stephen Tilles, MD, ACAAI former president, study co-author and consulting advisor for Aimmune Therapeutics, according to EurekAlert.\n\u201cReactions from the oral challenges at the end of the study were much milder than prior to treatment,\u201d Tilles said, according to EurekAlert.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story says that the treatment would be a new one, making clear that no other approved product exists for treating peanut allergy.\u00a0\nIt could have added that immunotherapy \u2014 or exposing allergy patients to small, controlled doses of the food they\u2019re allergic to \u2014 is not a new idea.", "answer": 1}, {"article": "Among the most dispensed: eat a healthy diet, keep a healthy weight, avoid alcohol and tobacco and stay away from certain medications, such as blood pressure and depression drugs.\n\u201cBut this is a much better done study than almost anything that\u2019s been done before on the subject.\u201d He notes that most previous studies did not randomly assign people to exercise groups and compare the outcome on sperm quality, but rather recorded sperm measures among men who reported their exercise habits after the fact.\nIn the current study, the men in the moderate intensity, continuous activity program showed the most improvements compared to men in the other two more intense groups.\nNow, researchers publishing in the journal have found that another lifestyle change\u2014exercise\u2014may also help improve sperm quality.\nWhile it\u2019s not entirely clear why, part of the reason may have to do with the fact that extreme exercise generates body heat, which can be detrimental to sperm health; for marathoners and people training at intense levels, finding ways to dissipate body heat is a major concern.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Novelty is established via this quote:\n\u201cThis fits reasonably well with what we thought about the effects of exercise,\u201d says Dr. Peter Schlegel, vice president of the American Society of Reproductive Medicine and chairman of urology at New York Presbyterian/Weill Cornell Medical Center. \u201cBut this is a much better done study than almost anything that\u2019s been done before on the subject.\u201d He notes that most previous studies did not randomly assign people to exercise groups and compare the outcome on sperm quality, but rather recorded sperm measures among men who reported their exercise habits after the fact.", "answer": 1}, {"article": "But an electrolyte imbalance caused by dehydration, influenza or other health problems that deplete the system of potassium, magnesium and other minerals also can cause cardiac arrest.\nThat's most likely what happened to Mr. Beck, whose heart arteries were clear.\nMr. Beck said he didn't regain full consciousness for nine days.\nA heart attack can prompt cardiac arrest -- a situation in which the heart rhythm goes chaotic, making it quiver rather than beat, Dr. Granato said.\nUPMC Presbyterian does about 50 hypothermic therapies a year, said Dr. Clifton Callaway, assistant professor of emergency medicine.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It is not clear from this story whether this is a new treatment or just a newly introduced treatment at this particular hospital. \nThe story stated \"The American Heart Association has approved the procedure in the wake of extensive overseas clinical trials\", however at the American Heart Association web site, there is mention of this treatment from a media advisory of February 20, 2002 \u2013 more than five years ago. \nAnd the American Heart Association doesn't technically \"approve\" any procedures \u2013 making this a simplistic, naive and inaccurate statement in the story.\u00a0 ", "answer": 0}, {"article": "reflect problems that cause squeaking, which it contends occurs in less than 1 percent of implants.\nDr. D\u2019Antonio, whose longstanding role in Stryker\u2019s product development efforts earned him $1.1 million in consulting payments from the company last year, said he had implanted 400 Tridents since the clinical trials began in 1996.\nNow that the squeaking has raised caution flags, researchers are weighing the noted durability of ceramic-on-ceramic hip joints like Stryker\u2019s Trident model against products with other combinations of materials.\nThat could force patients to undergo the very operation \u2014 a second replacement of the same hip joint \u2014 they had hoped to avoid by choosing ceramics.\nNow, tens of thousands of ceramic hips later \u2014 from Stryker and other makers that entered the field \u2014 many patients say their squeaking hips are interfering with daily life.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that Stryker introduced ceramic hip implants into the U.S. in 2003.", "answer": 1}, {"article": "Dr Weaver said: \"We have shown that all our patients in the study had their insulin doses reduced after taking metformin and have not suffered any serious adverse effect.\nFindings of the clinical trial are published today in the journal, Cardiovascular Diabetology.\nResearchers studied a treatment group of 23 people aged 19-64 who had Type 1 diabetes for up to 23 years and had no evidence of heart disease.\n\"The results, which indicate that metformin, a drug commonly used in the treatment of Type 2 diabetes, could also have a powerful effect in people with Type 1 diabetes is unexpected.\nExperts found that the stem cells of patients who took metformin were able to promote the repair of the blood vessels and there was an improvement in how vascular stem cells worked.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Since cardiovascular disease is a major risk for diabetic patients, research indicating that an existing (presumably inexpensive) drug may lower that risk clearly qualifies as significant enough to warrant a release, in spite of the fact that this was only a small, limited pilot study.", "answer": 1}, {"article": "In an email, Gunter said she frequently prescribes high-frequency TENS (pulses between 50 and 120 hertz at a low intensity) to treat patients who suffer through their periods: \"I have done so for more than 15 years.\nBut there's some reason for optimism: The device is basically a repackaging of another (cheaper) technology that has already been proven to help women who suffer with their monthly cycles.\nHe explained that the key to the device is TENS (transcutaneous electrical nerve stimulation), those electronic nerve stimulators you've probably seen in strip malls that hook up to the body to treat neck or back pain.\nAs far as gadgetry for women's health goes, this one is novel.\nFor now, it's only possible to preorder the device (at a cost of $85) and wait six months for it to ship.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that the Livia device has as yet to be characterized fully by the company, but at face value appears to be equivalent to a TENS unit, which have been used for menstrual pain for many years.", "answer": 1}, {"article": "\"Nicotine replacement therapies ... do not show any long-term effect on quitting even when combined with counseling,\" says researcher Gregory Connolly, DMD, director of the Center for Global Tobacco Control and professor of public health at the Harvard School of Public Health.\nThe new study, however, draws from the population.\nThe findings are at odds with clinical trials, Connolly says.\nBetter strategies are needed to prevent relapse, he tells WebMD.\nThe results of the new study are published online in Tobacco Control.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story says that the new study gives a more \u201creal world\u201d picture of nicotine replacement therapies.", "answer": 1}, {"article": "\"It's not far-fetched that the pharmaceutical industry will try to create a supplement of these microbiomes, much like was done with probiotics,\" she said.\n\"The abundance of these two bacteria were increased twofold when there was a pet in the house,\" said Kozyrskyj, adding that the pet exposure was shown to affect the gut microbiome indirectly--from dog to mother to unborn baby--during pregnancy as well as during the first three months of the baby's life.\nWhat's more, Kozyrskyj's study suggested that the presence of pets in the house reduced the likelihood of the transmission of vaginal GBS (group B Strep) during birth, which causes pneumonia in newborns and is prevented by giving mothers antibiotics during delivery.\nThe latest findings from Kozyrskyj and her team's work on fecal samples collected from infants registered in the Canadian Healthy Infant Longitudinal Development study build on two decades of research that show children who grow up with dogs have lower rates of asthma.\nIt's far too early to predict how this finding will play out in the future, but Kozyrskyj doesn't rule out the concept of a \"dog in a pill\" as a preventive tool for allergies and obesity.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release doesn\u2019t claim a novel intervention but does say that this research builds on existing research and increases understanding of the pet-allergy connection. We\u2019ll give them the benefit of the doubt on that.", "answer": 1}, {"article": "Tobias Hartmann, the project's coordinator, said, \"We have known for a while that diet can reduce the risk of developing dementia.\nThis is the first time a randomised, double-blind, clinical trial has shown that a nutritional intervention can help to conserve the ability of patients with very early AD (pre-dementia) to carry out everyday tasks, such as paying bills, or finding your way around, as measured by the Clinical Dementia Rating-Sum of Boxes (CDR-SB) - a combined measure for the ability to think and perform everyday tasks.\n\"This is exciting because it shows that in the absence of effective drug options, we really have found something that can help slow down some of the most distressing symptoms in very early AD (pre-dementia); especially in those who started the intervention early.\nThe clinical trial, headed by Professor Hilkka Soininen is part of a large EC project (LipiDiDiet) to explore the therapeutic and preventative impact of nutrition on neuronal and cognitive performance in ageing, AD and vascular dementia.\nAs part of the LipiDiDiet project, the first randomised clinical trial to investigate the effects of a medical food Fortasyn Connect (Souvenaid), in patients with very early AD (pre-dementia), has just been completed.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release claims novelty with this statement:\u00a0 \u201cThis is the first time a randomised, double-blind, clinical trial has shown that a nutritional intervention can help to conserve the ability of patients with very early AD (pre-dementia) to carry out everyday tasks, such as paying bills, or finding your way around, as measured by the Clinical Dementia Rating-Sum of Boxes (CDR-SB) \u2013 a combined measure for the ability to think and perform everyday tasks.\u201d While a nutrition drink to improve memory in people with early Alzheimer\u2019s disease would certainly be a novel addition to the treatment tool chest, we think the novelty boat already sailed three years ago when there was significant coverage of the three previous double-blind studies.", "answer": 0}, {"article": "The data indicate that for every 10,000 women in their 50s, those using estrogen would experience 12 fewer heart attacks, 13 fewer deaths and 18 fewer adverse events like blood clots or stroke in a given year, compared with those taking a placebo.\nThe research, part of the landmark Women\u2019s Health Initiative study, is likely to surprise women and their doctors, who for years have heard frightening news about the risks of hormone therapy.\nDr. Rowan Chlebowski, another author of the study and a medical oncologist at Los Angeles Biomedical Research Institute, said the findings underscored the fact that the risks and benefits of menopause hormones change depending on a woman\u2019s health status, her age and the type of hormone used.\nThe new findings, reported Tuesday in The Journal of the American Medical Association, come from 10,739 women in the Women\u2019s Health Initiative study who had previously had a hysterectomy, the surgical removal of the uterus.\nAn accompanying editorial in the journal was skeptical about the results, arguing that the design of the initiative, which is skewed toward older women and stopped all forms of hormone treatment after several years of use, does not match the way doctors typically prescribe treatment to women in their 50s at the onset of menopause.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t make any inappropriate claims about estrogen, and it does appropriately try to frame the novelty of the research \u2013 \u201ca finding that challenges the conventional wisdom about the risks of some hormones used in menopause.\u201d", "answer": 1}, {"article": "\u201cI\u2019ve been doing clinical trials for 30 years in C.F.\nThe drug also reduced the frequency of disease exacerbations that required treatment with antibiotics.\nShe said other results of the trial were encouraging.\nDr. Ramsey, a professor of pediatrics at the University of Washington, was briefed on the results by Vertex.\nMany do not live past age 40.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "", "answer": 1}, {"article": ".\nThat is why patients need a CT scan to confirm the type of stroke before receiving tPA.\nPast research showed the sooner that a clot-busting tPA drug is given after an ischemic stroke - one in which a clot is blocking blood flow - the better patients fare.\nResearchers analyzed results from 658 stroke patients who were treated with tPA - a drug that dissolves blood clots.\n\"Time is brain in acute stroke after vascular collaterals fail, and faster treatment yields better outcomes,\" said May Nour, M.D., Ph.D., lead researcher, interventional neurologist and director of UCLA's Mobile Stroke Rescue Program.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does not adequately establish the novelty of the study or the findings. It does briefly allude to previous research: \u201cPast research showed the sooner that a clot-busting tPA drug is given after an ischemic stroke \u2013 one in which a clot is blocking blood flow \u2013 the better patients fare.\u201d\nThere have been around a dozen trials on mobile stroke units in recent years, appearing primarily in neurology journals. Some examples:", "answer": 0}, {"article": "Autologous CD34?\nOutcomes from the \"ACT-34-CMI\" study, a two-year, phase II, randomized, double-blind, placebo-controlled clinical trial, will be published in an upcoming cardiac issue of Cell Transplantation.\nThe researchers concluded that for \"no option\" patients with class III/IV angina refractory that was unresponsive to conventional medical therapy and who were not candidates for revascularization, injection of CD34+ cells resulted in persistent improvement in angina at two years post-treatment.\nAccording to the researchers, the study demonstrated that CD34+ cells have the ability to restore the microcirculation and improve myocardial tissue perfusion.\nAll of the 167 patients participating in the ACT34-CMI study saw significant improvement in both angina frequency and exercise at 12 months and a trend toward decreasing major cardiac events.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "As we noted under \u201cCompare Alternatives,\u201d there are a host of other angina treatments out there. Because they aren\u2019t addressed, it\u2019s not clear what makes this treatment novel. The release tells readers that some \u201cpatients with advanced coronary artery disease\u2026frequently have symptoms after having had standard therapies and are left with limited treatment options.\u201d The release also states that CD34+ treatment \u201cis an attractive treatment option\u201d for these patients. But it doesn\u2019t tell readers why. Nor does it mention how CD34+ differs from the other \u201climited treatment options.\u201d\nThe release also does not establish what makes CD34+ cells attractive as a treatment.\u00a0 It says \u201cbecause recent studies pointed to the importance of CD34+ cell content in the bone marrow of patients with risk factors for coronary artery disease.\u201d\u00a0 Risk factors do not mean the person will get the disease, nor is there a clear connection between bone marrow and the heart here.", "answer": 0}, {"article": "A common heart drug called a beta blocker was associated with a striking increase in survival for women with ovarian cancer in a study that suggests a possible new strategy for treating a variety of tumors.\n\nResearchers analyzing a database of 1,425 women with the tough-to-treat cancer found those who had taken a certain type of beta blocker lived more than four years longer on average than those who hadn\u2019t been prescribed the drug. The women were taking the medicine to treat high blood pressure or another heart problem, not...", "question": "Does the story establish the true novelty of the approach?", "explanation": "A close call here. The story acknowledges previous research in this areas when it says, \u201cMouse and test-tube studies have shown that so-called nonselective beta blockers inhibit molecular pathways that promote tumor growth. Selective versions, designed to minimize side effects for heart patients, are less effective in hitting such targets.\u00a0Dr. Sood and his colleagues wondered if the same effect would be found in people.\u201d\u00a0That\u2019s good context, but the story could also have noted that a number of studies\u00a0have indeed examined the impact of beta-blocker use on ovarian cancer patients, and did not find the same prolonged survival rates that are reported on in this story. The researchers think that\u2019s because these earlier studies didn\u2019t distinguish between the two types of beta-blockers.", "answer": 1}, {"article": "Gene therapy proposed for bleeding disorders involves introducing DNA carrying the code to produce the specific clotting factor lacking in patients.\nThis success in large animals holds considerable potential for a safe, effective and long-lasting new treatment in humans with the same bleeding disorder.\nThe CHOP team collaborated with scientists at UNC who have a long-established colony of dogs for hematology research.\nOver the past 15 years, CHOP hematology researchers have performed clinical trials of gene therapy for hemophilia B that have helped define efficacy and dosing levels in humans.\nThe current study sets the stage for clinical trials in humans.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This gene therapy is novel for this particular condition. The news release should also be commended for pointing out that a similar gene therapy approach has been tested by the same researchers for hemophilia. It\u2019s admirable that they are not overselling the novelty of this approach by referencing their own previous work in related areas.", "answer": 1}, {"article": "Abbott Laboratories is betting heart patients will benefit from a new type of arterial stent that dissolves away when it is no longer needed.\n\nStents are scaffold-like devices used to prop open clogged heart arteries. Most stents are made of metal. But Abbott's new device, called Absorb, is made from a plastic-like material called polylactide that is commonly used in surgical sutures. The Absorb scaffold\u2014Abbott doesn't call it a stent\u2014is designed to completely fade away in two years and to cease supporting arteries at six...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The idea of a bioabsorbable stent is not new or unique to Abbott.\u00a0The concept was proposed in the early 1990\u2019s and the other players are also working on their own version. Although the story alludes to the fact that competitors might seek to follow Abbott\u2019s lead, it doesn\u2019t convey that other companies are already quite far along in their research. ", "answer": 0}, {"article": "on Sept. 2.\nMr. Schimmer\u2019s note was entitled \u201cFolotyn Prices High, Reiterate Outperform.\u201d He estimated annual sales of the drug in the United States reaching about $300 million by 2014.\n\u201cA peripheral T-cell lymphoma patient,\u201d he said, \u201cat first blush will see this therapy as a very good thing.\u201d\n\nAllos, which is still unprofitable, has lost $350 million since its founding in 1992 and failed to win approval of a previous drug.\nIn a note to clients in October, Joshua Schimmer, an analyst at Leerink Swann, estimated that a typical treatment would last 3.5 months and cost $126,000, or about $36,000 a month.\nEven to try the drug for the first seven-week cycle to see if it works would cost over $50,000.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story clearly states that Folotyn is new.\u00a0 It could have stated that a host of older and less expensive treatment options are currently available.", "answer": 1}, {"article": "Recently, he says, urologists \"have begun to realize these criteria are not adequate.\nThey say what's really needed is a set of tests that classify prostate tumors by what genes are turned on or off in the cells.\nStill, both study author Reese and Andriole say the new study may serve as a wakeup call to those who are over-relying on the clinical staging system.\nWhen these errors occur, the study says, doctors most often conclude the cancer is less serious than it really is.\nThe new study discrediting the test, coupled with persistent questions about how useful prostate screening is for most men anyway, add up to a whole lot of discussion points patients should take to their doctors.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story reported that clinical staging has been recommended for use by the American College of Surgeons Commission on Cancer for the past 10 years and gave one doctor\u2019s statement that \u201cthis is the first study that quantifies the magnitude of the inadequacy.\u201d", "answer": 1}, {"article": "Arthritis pain is caused by bones rubbing together after protective cartilage is damaged or worn away.\nAfter years of cortisone treatments and therapy, wrist replacement became a last resort.\nShe still can't lift more than 11 pounds, but the pain has greatly subsided.\nPotential patients must be evaluated for other causes of pain, Collins noted, because problems with thumbs or other hand parts can make the wrist hurt.\nMore than a dozen bones lie beneath the skin and muscles of the hand and wrist, compared with two or three for those larger joints.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story points out that wrist replacement surgery has been around for decades. The story\u2019s single source of medical information\u2014a surgeon\u2013suggests that newer versions of the implants enable surgeons to retain more of the patient\u2019s native bone. ", "answer": 1}, {"article": "\"The issue is, can you detect these in patients that don't have advanced cancer?\" Venook said. \"The answer is, we don't know.\" The numbers tested by the MD Anderson researchers -- 251 patients with pancreatic cancer (five of whom had very early lesions), 32 with chronic pancreatitis and 120 healthy controls -- aren't nearly large enough to draw such conclusions. And getting a clear answer, Venook said, would probably require lengthy and expensive studies on very large populations.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes what is novel about the test \u2014 the fact that it has the potential to detect cancer at an early, more treatable stage.\u00a0The story could have done more to establish whether there has been other research into tests for pancreatic cancer and how the new test builds upon those previous efforts.", "answer": 1}, {"article": "Individuals with panic chronically hyperventilate, even when not experiencing a panic attack.\nNinety percent of patients in this study experienced a significant improvement in PTSD symptoms at two months and six months post-treatment.\nTheir first product, Freespira, is an FDA-cleared treatment for individuals suffering from panic disorder, panic attacks and other symptoms of panic.\nThe peer-reviewed published multi-center Freespira clinical trial, presented by Dr. Tolin, demonstrated that 71% of patients were panic attack free immediately after treatment and 79% of patients were panic attack free 12 months post-treatment.\nEarly data from a fifth study reported on Freespira treatment for patients with Post-Traumatic Stress Disorder (PTSD).\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release does not provide proof of the claim that there is a \u201cnew\u201d clinical research study supporting the headline.", "answer": 0}, {"article": "Legumes, beans, whole grains and some seeds have it, as do uncooked potatoes and unripe bananas.\nBut that\u2019s not the case with resistant starches, so named because they resist digestion.\n\u201cIn my belief, that\u2019s what\u2019s protected them against some of the ravages of the more modern-day high carbohydrate diet.\u201d\n\nLuckily, resistant starch is found in a range of delicious foods.\nMost intriguing and surprising of all is that so many leftovers contain resistant starch.\nThose benefits\u2014getting digested slower, being converted into fatty acids and sustaining colonies of gut bacteria\u2014set resistant starch apart.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that these types of starches are being studied in a variety of ways.", "answer": 1}, {"article": "In Columbus, New York City and several other cities, ambulances take cardiac arrest patients whose hearts have been restarted by electric shock, but who remain unconscious, to hospitals that provide a cooling therapy that lowers the body temperature.\nThough it's not unusual to have debate over new therapies, the benefits of induced hypothermia is not a new discovery.\nColumbus is already part of the program, called Cardiac Arrest Registry to Enhance Survival.\nChances of surviving depends largely on where you live.\nEven those who do are often neurologically impaired.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u2019s clear from the story that this is not a new approach. ", "answer": 1}, {"article": "So patients are caught in the middle.\"\nAnd the study's authors note that the ImPAT approach has the potential to be easily and inexpensively adopted by addiction treatment centers and groups worldwide, through team members trained in standard psychological techniques.\nIn an editorial accompanying the new paper, another addiction and pain specialist, William C. Becker, Ph.D. of Yale University and the Connecticut VA, notes that the new results are even more impressive because ImPAT was compared with another psychosocial approach.\nThe larger ongoing study, based in an abstinence-based treatment facility in Michigan and funded by the National Institute on Drug Abuse, has largely avoided that issue by decreasing the delay between study recruitment and the start of the treatment groups, Ilgen says.\nIlgen and his colleagues hope their results will help bring the techniques into addiction treatment settings, where the cognitive behavioral therapy approach is often used.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release makes clear that the two treatment techniques that constitute ImPAT are rarely used jointly, but are both fairly common in pain treatment settings. However, as the release notes, pain treatment clinics and centers often decline to work with patients who have substance abuse problems.", "answer": 1}, {"article": "\u201cI don\u2019t want to throw cold water on an interesting thing, but that\u2019s what it is \u2014 an interesting thing,\u201d Gallo said.\n\u201cOur results strongly suggest that cure of HIV has been achieved in this patient,\u201d they wrote in the journal Blood.\n\u201cIt is possibly a cure, that\u2019s for sure, you won\u2019t know for absolute sure until the person dies and undergoes extreme PCR (genetic) analysis of post-mortem tissue.\u201d\n\nThe mutation affects a receptor, a cellular doorway, called CCR5, that the AIDS virus uses to get into the cells it infects.\nThe patient, who had both HIV infection and leukemia, received the bone marrow transplant in 2007 from a donor who had a genetic mutation known to give patients a natural immunity to the virus.\n\u201cFrom these results, it is reasonable to conclude that cure of HIV infection has been achieved in this patient,\u201d they wrote.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story apppropriately points out the uniqueness of the report. The patient presented with leukemia and HIV and a donor was available who happened to have te CCR5 mutation.", "answer": 1}, {"article": "Trans fats raise bad cholesterol, lower good cholesterol and ultimately increase the risk of heart attacks and strokes.\n\u201cHere we find on a population level when we restrict them, it benefits society by reducing heart attacks and strokes.\u201d\n\nThe findings suggest the FDA\u2019s action will lead to health benefits across the country, he added.\nStill, the study can\u2019t say the trans fat restrictions caused fewer admissions in those counties.\nNo study looked at non-fatal cardiovascular issues like hospitalizations due to heart attacks and strokes, however.\nFor the new study, the researchers compared data on people hospitalized between 2002 and 2013 for heart attacks or strokes in counties that did or didn\u2019t restrict trans fats.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The text notes that earlier research\u00a0looked only at reductions in mortality; this new study expands that effort by focusing on hospitalizations.", "answer": 1}, {"article": "Finasteride blocks the conversion of testosterone to dihydrotestosterone, a hormone active mostly in the prostate and the scalp, and that all prostate cancers need to grow.\nThe reason was that the results were overwhelmingly compelling \u2014 men taking the drug were not getting prostate cancer.\nNow, though, prostate cancer specialists have a new problem: How can they change the drug\u2019s image?\nWith this new analysis, many prostate cancer specialists, including Dr. Scardino, say their view of the drug has completely changed.\nBut, as Dr. Scardino pointed out in an editorial five years ago in The New England Journal of Medicine that accompanied the study, it appeared that 6.4 percent of the men who took the drug got fast growing, ominous-looking tumors.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story begins with the phase \"For the first time\u2026.\" \u2013 an odd choice of words for an effect of the drug that was discussed in the medical literature for at least 3 years. \u00a0Although the story was about the results of a new analysis of data, that opening line suggests a novelty to the approach that isn\u2019t true.\u00a0 In fact, the story itself shows it\u2019s not the first time \u2013 that \"In March 2003, 15 months before the study\u2019s scheduled end, its directors halted it abruptly. The reason was that the results were overwhelmingly compelling \u2014 men taking the drug were not getting prostate cancer.\"\u00a0 It\u2019s like an opening line begging for page 1 attention.\u00a0 ", "answer": 0}, {"article": "Feb. 10, 2011 (Los Angeles) -- Giving clot-busting drugs to people with mild strokes could prevent more than 2,000 of them from becoming disabled each year, researchers say.\nThose parts of the brain soon start to die.\nIn fact, one in three people who suffer a mild stroke are disabled three months later, Khatri says.\nIt's been assumed that people with mild strokes \"generally [do] well and the risk of tPA treatment, which includes a slight but significant risk of life-threatening bleeding in the brain, would not be worth the benefit,\" she says.\nBut people with mild strokes are typically denied tPA because the studies that established its effectiveness excluded mild cases, says Pooja Khatri, MD, of the University of Cincinnati.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u2019s clear from the story that it would be a relatively novel approach to give tPA to mild stroke patients, since it appears it is hardly ever done now.", "answer": 1}, {"article": "Second, the DRCR Network study is the first multi-center, randomized clinical trial to show how ranibizumab and the laser work together to improve treatment,\" Williams said.\nThe American Academy of Ophthalmology will review the study findings and make recommendations on whether Lucentis plus laser treatment should be the preferred treatment for a large number of patients with DME.\nBut researchers say it can also improve vision in people with DME, a common form of diabetic retinopathy.\nThe study, published online in the journal Ophthalmology, was conducted by the Diabetic Retinopathy Clinical Research (DRCR) Network.\nThis is a \"seminal\" study,\" added Dr. George A. Williams, a board member of the American Academy of Ophthalmology and chair of the ophthalmology department at Oakland University William Beaumont School of Medicine.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story calls it \"a new drug.\"\u00a0 It\u2019s not. It\u2019s already approved for another eye disease, age-related macular degeneration.", "answer": 0}, {"article": "God watches out for fools and little children.\n\"That's huge,\" said lead author Fran Weaver, a researcher with the Hines VA Hospital in Hines, Ill.\n\nShe said the best drugs provide only one to two hours of added improvement, or \"on time.\"\nThose who got the therapy also had significantly more improvement in other measures of symptoms, according to the study that will appear today in the Journal of the American Medical Association.\nDeep brain stimulation is not an option for the 20% to 30% of Parkinson's patients who also have dementia, said Hiner, of Froedtert Hospital.\nNausieda said much of the benefit found in the study could be due to a placebo effect.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "While the lede implies the surgery is exotic, later in the story the report makes clear that it is done with some regularity and is being studied for use on other conditions. \nThe reporter includes specifics: About 15 percent of Parkinson\u2019s patients may qualify for the surgery, yet only 2 percent of patients get it. \nIdeally this information would have been placed higher in the story so Parkinson\u2019s patients and caretakers understand the limited applicability.\u00a0 ", "answer": 1}, {"article": "When it reaches the area of the heart that causes abnormal rhythms, the tissue is ablated, or destroyed.\nPatients in the Medtronic-sponsored trial who underwent the cryoablation procedure \u2014 which involves using a catheter to freeze away the heart tissue where the problem originates \u2014 was just as safe as drugs used to treat the condition and far more effective, meeting the study\u2019s primary goal of eliminating atrial fibrillation one year after the procedure.\nA small pilot study funded by St. Jude Medical Inc STJ.N compared the two therapies in a sicker population of patients and also found that the procedure worked better than drugs.\nDubbed Stop-af, the Medtronic trial showed that almost 70 percent of patients who had cryoablation remained free of the condition after one year, compared with just 7 percent of patients who received drug therapy, according to data presented at the American College of Cardiology meeting in Atlanta.\nOver the past decade, more patients have been referred for ablation procedures when drugs proved ineffective.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Towards the end of the story, there was a clear statement that there is another device on the market that has been used for a long time in the treatment of atrial fibrillation.", "answer": 1}, {"article": "Sitting has been identified as a risk factor for early mortality, independent of the presence of a disease, such as cancer or diabetes.\n\u201cThese results suggest that non-exercise active thermogenesis, which we call NEAT, can increase movement and calorie burning, and may have the potential to impact health,\u201d said Horswill, the senior author on the study.\nParticipants in the study familiarized themselves with the workstations during one visit.\n\u201cThis is more evidence that NEAT, something everyone can do throughout the day, may be an important strategy for improving health, and even reducing early death,\u201d said Horswill.\n\u201cWe expected to see the metabolic rate increase with each progressive stage, but instead found that metabolic rates from movement while seated were either equal to or higher than rates while standing.\u201d\n\nHorswill says the study needs to be further validated, but that the findings should be especially applicable to individuals poised to benefit from NEAT but unable to access popular standing desks because of injury, disability or discomfort.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This study is one in a growing body of research about non-exercise activity thermogenesis (NEAT), which is the energy we expend in our daily lives when not sleeping, eating, or doing sports-like levels of exercise. NEAT incorporates our fidgeting, our daily walking around, even our keyboard typing. This study is novel in that it found that, counter-intuitively, leg exercises while sitting might increase metabolism more than using a standing desk. But the operative word here is \u201cmight\u201d \u2013based on the quality of evidence the news release was likely premature, and did not highlight the many weaknesses in the study.", "answer": 1}, {"article": "In a statement, Dr. Lesley Russell, Cephalon's chief medical officer, said:\n\nThe most common side effects for Nuvigil, include diarrhea, headache, insomnia and nausea, according to Cephalon.\nThe regulators just gave a second thumbs down to drugmaker Cephalon's application to sell Nuvigil as a remedy for jet lag.\nBut the regulators weren't buying the evidence put forward by the company to prove the medicine's benefits in treating travelers' \"excessive sleepiness\" outweighed its risks.\nFinally, it should be said that the Drug Enforcement Administration has made Nuvigil a federally controlled substance because it has the potential for abuse and dependence.\nCephalon soldiered on, giving FDA more data.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "In a brief piece, the story gave a good history of this drug and now its second \u201cthumbs down\u201d from regulators on the application for marketing approval for jet lag.", "answer": 1}, {"article": "\"My reaction was, 'Well, you smoked for 30 years.\nThe study looked at more than 2,000 patients with Stage 1 non-small cell lung cancer who had surgery to remove their tumor.\nAnd, after five years, almost 9 out of 10 patients were alive and cancer free.\nBut many patients can survive and even thrive after surgery, says Dr. Prasad Adusumilli, a thoracic surgeon at Memorial Sloan Kettering Cancer Center in New York.\nOne year after surgery, more people had died from other causes than died from lung cancer.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article implicitly suggests\u00a0the novelty of the study is\u00a0that it overturns conventionally held beliefs about the benefits of\u00a0surgery in older lunger cancer patients.\u00a0But that\u2019s not really the case.\nThe researchers chief\u00a0conclusion was \u201cIn patients who undergo curative-intent resection of stage I NSCLC, noncancer-specific mortality is a significant competing event, with an increasing impact as patient age increases.\u201d In plain language, many older lung cancer patients die of non-cancer problems. This doesn\u2019t prove that lung cancer surgery is beneficial and leads to a longer, better lifespan than\u00a0other options. Nor does it prove the surgery was the best choice.", "answer": 0}, {"article": "More women are undergoing genetic testing after a diagnosis of breast cancer, and improvements in both mastectomy and breast-reconstruction techniques have made the option of a double reconstruction less daunting.\nSeveral developments may be driving the trend toward prophylactic mastectomies, experts said.\nThough the researchers had limited information about the patients, Dr. Tuttle suggested that younger women might be choosing the procedure because their cancers tended to be very aggressive, and they had more years ahead of them in which a second cancer might develop.\nThe numbers were much higher among women who had the breast with cancer removed, rather than a lumpectomy.\nHe and other experts emphasized that though the removal of the healthy breast sharply reduced the risk of a new cancer developing in that breast \u2014 the risk is not zero because some tissue can remain \u2014 it was the cancer that had already been diagnosed that posed the greatest threat to a patient\u2019s life.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The increase in double mastectomy as prophylaxis after a cancer diagnosis is a new finding. The focus of the story discusses this data and attempts to explain this trend. ", "answer": 1}, {"article": "Happiness won\u2019t help you live longer (but unhappiness won\u2019t kill you either)\n\nGuinea is finally declared Ebola-free, but that does not mean the crisis is over\n\nMost popular Washington Post health stories of 2015: A mother tells her story of how she lost her darling daughter a few weeks short of her 29th birthday when she stepped in front of a train in Baltimore.\nNow a large new analysis involving 250,000 patients shows that these medications may be as effective and safe as their older cousins, the angiotensin converting enzyme, or ACE inhibitors.\nBut some doctors and researchers were puzzled by the fact that in head-to-head comparisons between the two classes of drugs they appeared to equally safe and effective.\nThat led many doctors and standards groups to conclude that ACE inhibitors were more effective than ARBs.\nMost significantly, research showed a significant effect in reducing the risk of death with ACE inhibitors but not with ARBS.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty here is simply that this meta-analysis is aimed at clarifying uncertainty surrounding the comparison of these two classes of drugs and their efficacy in treating cardiovascular disease.\u00a0 The prevalence of this condition within the population makes it a topic of broad interest, both among the public and among the professionals who treat them.", "answer": 1}, {"article": "As of 2014, only 12 states allowed basic EMS staff to administer naloxone for a suspected opioid overdose; all 50 states allow advanced EMS staff to administer the overdose reversal treatment.\nDepartment of Health and Human Services Secretary Sylvia M. Burwell has made addressing opioid abuse, dependence, and overdose a priority and work is underway at multiple HHS agencies on this important issue.\n\u201cMany of these deaths can be prevented by improving prescribing practices to prevent opioid addiction, expanding the use of medication-assisted treatment, and increasing use of naloxone for suspected overdoses.\nAccording to the study findings, advanced EMS staff were more likely than basic EMS staff to administer naloxone.\nA majority of states have adopted national guidelines that prohibit basic EMS staff from administering the drug as an injection.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "It would have been helpful to put the research in the context of previous work. Naloxone is not new. But are the results being reported new and surprising? What was known about naloxone use among EMTs previously?", "answer": 0}, {"article": "Additional UT Southwestern researchers include lead authors Dr. Wenfang Chen, Haley Hill, Alana Christie, and Min Soo Kim, as well as Eboni Holloman, Andrea Pavia-Jimenez, Farrah Homayoun, Dr. Yuanqing Ma, Dr. Nirav Patel, Dr. Guiyang Hao, Qurratulain Yousuf, Allison Joyce, Dr.\nHIF-2 inhibitors also are the target of UTSW's recent $11 million SPORE (Specialized Program of Research Excellence) award.\nPart of the SPORE grant, one of just two directly related to kidney cancer in the nation, is focused on further researching HIF-2 inhibitors.\n\"HIF-2 is believed to be the most important driver of kidney cancer.\nThe findings show that HIF-2 is a promising target to combat kidney cancer, said Dr. Brugarolas, senior author and a Virginia Murchison Linthicum Scholar in Medical Research at UT Southwestern.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "It is pretty clear this is a novel approach, and we do get some explanation of why HIF-2 may have been disregarded in the past.", "answer": 1}, {"article": "Wasting syndrome is characterized by a loss of weight and muscle atrophy, and largely found in patients who suffer from cancer, kidney disease, chronic obstructive pulmonary disease, and heart failure.\nThe intellectual property associated with this discovery was recently licensed by the UI Research Foundation to Innovus Pharma, an over-the-counter consumer goods and specialty pharmaceutical company that commercializes non-prescription medicine and consumer care products.\n\u201cWe tested these compounds in sedentary mice and found a dramatic improvement in exercise endurance and a mild increase in muscle size of certain muscle groups,\u201d Sah says.\n\u201cThe treatment of cachexia just doesn\u2019t exist.\nThe discovery was a \u201cserendipitous finding\u201d in the lab of Rajan Sah, M.D., Ph.D., assistant professor of Internal Medicine and Molecular Physiology and Biophysics at the University of Iowa.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "If combating cachexia were as simple as using compounds from\u00a0ordinary spices, then this would be adequately novel. But neither the release nor the research as yet are available tend to bear that out. The work is done in animals, not humans. The compounds are not identified. And the explanation of benefits from those compounds is inadequate for readers to have confidence in these claims.", "answer": 0}, {"article": "Cao looked at data from over 86,000 women who were part of the Nurses' Health Study between 1980 and 2012 and over 43,000 men who were part of the Health Professionals Follow-Up Study from 1986 to 2012.\n\"This study found strong evidence that aspirin use may reduce cancer death.\nCao hopes her study will continue to broaden the body of research to include cancer-related deaths overall.\nTherefore the findings are believed to be very robust, and suggest that aspirin, which is widely available, cheap and has limited toxicity, has the potential to have widespread benefit on cancer mortality for breast, colon, lung and prostate cancer.\"\n\"Evidence has been accumulating very rapidly showing aspirin works in reducing cancer and cardiovascular disease mortality,\" Cao said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t clearly establish what\u2019s new about this research\u2013how, exactly, does it add to what\u2019s already known about aspirin and cancer risk?\nThe news release indicates the novel finding is this: \u201cThese findings suggest that aspirin\u2019s established benefits in cardiovascular disease and colorectal cancer reduction may extend to other common causes of death, including several major cancers.\u201d", "answer": 0}, {"article": ".\n\"For the first time, this study demonstrates the use of OCT for imaging tumor margins within the tumor cavity, in the patient, during surgery,\" Boppart said.\nThe researchers will continue clinical studies with the OCT device, looking at other types of solid-state tumors.\nDiagnostic Photonics, a start-up company Boppart co-founded that also collaborated on the study, is commercializing the OCT probe technology for broader use.\nThe interdisciplinary research team led by Stephen Boppart, a University of Illinois professor of electrical and computer engineering and of bioengineering, performed the study on 35 patients with breast cancers at the Carle Foundation Hospital in Urbana, Illinois.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "As noted above, the release could have mentioned a competing device that has already been found able to distinguish pretty well between normal and cancerous tissue, but not in real time with a portable device in the operating room. However, the release does quote one of the researchers who establishes what is new here:\u00a0\u201cFor the first time, this study demonstrates the use of OCT for imaging tumor margins within the tumor cavity, in the patient, during surgery.\u201d We\u2019ll rate this Satisfactory.", "answer": 1}, {"article": "April 18, 2011 -- The FDA has approved a new noninvasive portable device for the treatment of a deadly type of brain tumor. The device uses electrical fields to slow and possibly reverse tumor growth.\n\nThe device, manufactured by Novocure, is called the NovoTTF-100A System and is meant for adults with glioblastoma multiforme that recurs or progresses after chemotherapy and radiation treatment.\n\nGlioblastoma multiforme is a common type of brain cancer, and the tumor is highly resistant to standard treatments, such as surgery, radiation, and chemotherapy, the FDA says in a statement.", "question": "Does the story establish the true novelty of the approach?", "explanation": "We\u2019re only told that this is a new device, newly approved by the FDA. \u00a0But its unique place in the treatment of this brain tumor type is not clearly defined. In reality, the use of weak electrical fields to interrupt cancer cell growth has been known for some time. But we\u2019re not given any of that context.", "answer": 0}, {"article": "A colonoscopy isn\u2019t something you get just for giggles. Beyond the obvious unpleasantness, there\u2019s the small but real risk of complications that in rare cases can lead to hospitalization or even death.\n\nThat\u2019s why the American Cancer Society and other groups recommend that people screened for colorectal cancer using a colonoscopy wait a decade in between tests if no polyps or other signs of potential cancer are found. Polyps are slow-growing, and the benefits of being screened more frequently than that don\u2019t seem to outweigh the risks \u2026", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of this study was made clear in the story.", "answer": 1}, {"article": "Labor may be induced by breaking the amniotic sac or by using hormones called prostaglandins or medication such as oxytocin, which can set off contractions.\n\u201cThere are anywhere between 25,000 to 30,000 stillbirths a year in the United States.\u201d\n\nLockwood and Norwitz\u2019s support for induction at 39 weeks not only surprised many of the doctors at the session, it also upset those who believe less intervention is the safest route for mother and baby.\n\u201cIt\u2019s obvious that a blanket policy of 39-week inductions would not affect all of the stillbirths that happen before 39 weeks,\u201d Dekker said, adding that the CDC report concludes, \u201cDespite intensive investigations, for a substantial number of fetal deaths a specific cause of death cannot be determined.\u201d\n\nAnd, Dekker said, the public has the misconception that inductions are simple, noninvasive procedures.\nFor the women who waited for labor to start on its own, about half ended up being induced for medical complications.\nAnd as Lockwood reviewed research, he found that he was more and more in agreement with that point of view.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story refers to recent studies, but again there are no details provided, so readers are not told what \u201crecent\u201d means. Have the studies been around for years, but just escaped the notice of the featured physicians until they checked the literature in order to prepare for their panel session? Or is there really some important new evidence that wasn\u2019t available when ACOG and other groups issued the latest version of their recommendations about inducing labor? The story doesn\u2019t answer those questions.", "answer": 0}]